<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>SAPHRIS - asenapine maleate tablet </strong><br>STAT RX USA LLC<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use SAPHRIS<span class="Sup">®</span> (asenapine) safely and effectively. See full prescribing information for SAPHRIS.<br>SAPHRIS (asenapine) sublingual tablets<br>Initial U.S. Approval: 2009</div>
<div class="Warning"><div>
<h1 class="Warning"><span class="Bold">WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">DEMENTIA</span>-RELATED <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">PSYCHOSIS</span></span></h1>
<h1 class="Warning"><span class="Bold Italics">See full prescribing information for complete boxed warning.</span></h1>
<p class="Highlighta"><span class="Bold">Elderly patients with <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span>-related <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span> treated with antipsychotic drugs are at an increased risk of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. SAPHRIS is not approved for the treatment of patients with <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span>-related <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span>. (<a href="#S5.1">5.1</a>)          </span> </p>
</div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>RECENT MAJOR CHANGES</span></h1>
<div>
<a name="i3c9318bf-ade8-43d8-8784-2f0849044c46"></a><table width="80%">
<col align="left" valign="middle" width="70%">
<col align="right" valign="middle" width="30%">
<tbody class="Headless">
<tr class="Botrule First Toprule">
<td align="left">Indications and Usage, <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">Schizophrenia</span> (<a href="#S1.1">1.1</a>) </td>
<td align="right">09/2010</td>
</tr>
<tr>
<td align="left">Indications and Usage, Bipolar Disorder (<a href="#S1.2">1.2</a>) </td>
<td align="right">09/2010</td>
</tr>
<tr>
<td align="left">Dosage and Administration, <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">Schizophrenia</span> (<a href="#S2.2">2.2</a>) </td>
<td align="right">09/2010</td>
</tr>
<tr class="Botrule Last">
<td align="left">Dosage and Administration, Bipolar Disorder (<a href="#S2.3">2.3</a>)</td>
<td align="right">09/2010</td>
</tr>
</tbody>
</table>
</div>
</div>
<div></div>
<div class="Warning"><div>
<h1 class="Warning"><span class="Bold">WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">DEMENTIA</span>-RELATED <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">PSYCHOSIS</span></span></h1>
<h1 class="Warning"><span class="Bold Italics">See full prescribing information for complete boxed warning.</span></h1>
<p class="Highlighta"><span class="Bold">Elderly patients with <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span>-related <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span> treated with antipsychotic drugs are at an increased risk of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. SAPHRIS is not approved for the treatment of patients with <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span>-related <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span>. (<a href="#S5.1">5.1</a>)          </span> </p>
</div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div>
<p class="Highlighta">SAPHRIS is an atypical antipsychotic indicated for: </p>
<ul>
<li>Treatment of <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span>. (<a href="#S1.1">1.1</a>)<br>						Efficacy was established in two 6-week clinical trials and one maintenance trial in patients with <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span> in adults. (<a href="#S14.1">14.1</a>)</li>
<li>Acute treatment, as monotherapy or adjunctive therapy, of <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">manic</span> or mixed episodes associated with <span class="product-label-link" type="condition" conceptid="432876" conceptname="Bipolar I disorder">bipolar I disorder</span>. (<a href="#S1.2">1.2</a>)<br>Efficacy was established in two 3-week monotherapy trials and in one 3-week adjunctive trial in patients with <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">manic</span> or mixed episodes associated with <span class="product-label-link" type="condition" conceptid="432876" conceptname="Bipolar I disorder">bipolar I disorder</span> in adults. (<a href="#S14.2">14.2</a>)</li>
</ul>
</div>
<div></div>
<div>
<div></div>
<div></div>
</div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div>
<a name="i10980a6e-b687-4ea4-8e35-54805d1f8257"></a><table width="80%">
<col align="left" valign="top" width="25%">
<col align="center" valign="top" width="25%">
<col align="center" valign="top" width="25%">
<col align="center" valign="top" width="25%">
<thead><tr class="First Last">
<th align="left"></th>
<th align="center">Starting Dose</th>
<th align="center">Recommended Dose</th>
<th align="center">Maximum Dose</th>
</tr></thead>
<tbody>
<tr class="First">
<td align="left"><span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">Schizophrenia</span> – acute treatment in adults (<a href="#S2.2">2.2</a>)</td>
<td align="center">5 mg sublingually twice daily<br>
</td>
<td align="center">5 mg sublingually twice daily</td>
<td align="center">10 mg sublingually twice daily</td>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">Schizophrenia</span> – maintenance treatment in adults (<a href="#S2.2">2.2</a>)<br>
</td>
<td align="center">5 mg sublingually twice daily for one week<br>
</td>
<td align="center">10 mg sublingually twice daily</td>
<td align="center">10 mg sublingually twice daily</td>
</tr>
<tr>
<td align="left">Bipolar <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">mania</span> – adults:<br>monotherapy (<a href="#S2.3">2.3</a>)</td>
<td align="center">10 mg sublingually twice daily</td>
<td align="center">5–10 mg sublingually twice daily</td>
<td align="center">10 mg sublingually twice daily</td>
</tr>
<tr class="Last">
<td align="left">Bipolar <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">mania</span> – adults:<br>as an adjunct to lithium or valproate (<a href="#S2.3">2.3</a>)</td>
<td align="center">5 mg sublingually twice daily</td>
<td align="center">5–10 mg sublingually twice daily<br><br>
</td>
<td align="center">10 mg sublingually twice daily</td>
</tr>
</tbody>
</table>
<p class="Highlighta"><span class="Bold">Administration: Do not swallow tablet.</span> SAPHRIS sublingual tablets should be placed under the tongue and left to dissolve completely. The tablet will dissolve in saliva within seconds. Eating and drinking should be avoided for 10 minutes after administration. (<a href="#S2.1">2.1</a>, <a href="#S17.1">17.1</a>) </p>
</div>
<div></div>
<div>
<div></div>
<div></div>
</div>
<div><div></div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div>
<p class="Highlighta">Sublingual tablets: 5 mg and 10 mg (<a href="#S3">3</a>) </p>
<p class="Highlighta">Sublingual tablets, black cherry flavor: 5 mg and 10 mg (<a href="#S3">3</a>) </p>
</div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><p class="Highlighta">None (<a href="#S4">4</a>) </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><ul>
<li>
<span class="Italics">Cerebrovascular Adverse Events: </span>An increased incidence of cerebrovascular adverse events (e.g., <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, transient ischemic attack) has been seen in elderly patients with <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span>-related psychoses treated with atypical antipsychotic drugs. (<a href="#S5.2">5.2</a>)</li>
<li>
<span class="Italics"><span class="product-label-link" type="condition" conceptid="379802" conceptname="Neuroleptic malignant syndrome">Neuroleptic Malignant Syndrome</span>:</span> Manage with immediate discontinuation and close monitoring. (<a href="#S5.3">5.3</a>)</li>
<li>
<span class="Italics"><span class="product-label-link" type="condition" conceptid="4010823" conceptname="Tardive dyskinesia">Tardive Dyskinesia</span>:</span> Discontinue if clinically appropriate. (<a href="#S5.4">5.4</a>)</li>
<li>
<span class="Italics"><span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">Hyperglycemia</span> and <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">Diabetes</span> Mellitu</span>s<span class="Italics">:</span> Monitor patients for symptoms of <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span> including <span class="product-label-link" type="condition" conceptid="432454" conceptname="Excessive thirst">polydipsia</span>, <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">polyuria</span>, <span class="product-label-link" type="condition" conceptid="438872" conceptname="Excessive eating - polyphagia">polyphagia</span>, and <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>. Monitor glucose regularly in patients with, and at risk for, <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>. (<a href="#S5.5">5.5</a>)</li>
<li>
<span class="Italics"><span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">Weight Gain</span></span>: Patients should receive regular monitoring of weight. (<a href="#S5.6">5.6</a>)</li>
<li>
<span class="Italics"><span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">Orthostatic Hypotension</span> and <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">Syncope</span>:</span> <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span>, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span> or <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>, and <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span> may occur, especially early in treatment. Use with caution in patients with known cardiovascular or cerebrovascular disease, and in antipsychotic-naïve patients. (<a href="#S5.7">5.7</a>)</li>
<li>
<span class="Italics"><span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">Leukopenia</span>, <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">Neutropenia</span>, and <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">Agranulocytosis</span></span> have been reported with antipsychotics. Patients with a pre-existing low white blood cell count (WBC) or a history of <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>/<span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> should have their complete blood count (CBC) monitored frequently during the first few months of therapy and SAPHRIS should be discontinued at the first sign of a decline in WBC in the absence of other causative factors. (<a href="#S5.8">5.8</a>)</li>
<li>
<span class="Italics">QT Prolongation:</span> Increases in QT interval; avoid use with drugs that also increase the QT interval and in patients with risk factors for prolonged QT interval. (<a href="#S5.9">5.9</a>)</li>
<li>
<span class="Italics"><span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizures</span>:</span> Use cautiously in patients with a history of <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> or with conditions that lower the <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> threshold. (<a href="#S5.11">5.11</a>)</li>
<li>
<span class="Italics">Potential for Cognitive and Motor Impairment:</span> Use caution when operating machinery. (<a href="#S5.12">5.12</a>)</li>
<li>
<span class="Italics"><span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">Suicide</span>:</span> The possibility of a <span class="product-label-link" type="condition" conceptid="4219484" conceptname="Suicide attempt">suicide attempt</span> is inherent in <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span> and bipolar disorder. Closely supervise high-risk patients. (<a href="#S5.14">5.14</a>)</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta">Commonly observed adverse reactions (incidence ≥5% and at least twice that for placebo) were (<a href="#S6.2">6.2</a>): </p>
<ul>
<li>
<span class="Underline"><span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">Schizophrenia</span></span>: <span class="product-label-link" type="condition" conceptid="4108925" conceptname="Akathisia">akathisia</span>, oral <span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">hypoesthesia</span>, and <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>.</li>
<li>
<span class="Underline">Bipolar Disorder (Monotherapy)</span>: <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="373747" conceptname="Extrapyramidal disease">extrapyramidal symptoms</span> other than <span class="product-label-link" type="condition" conceptid="4108925" conceptname="Akathisia">akathisia</span>, and <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight increased</span>.</li>
<li>
<span class="Underline">Bipolar Disorder (Adjunctive)</span>: <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span> and oral <span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">hypoesthesia</span>.</li>
</ul>
<p class="Highlighta">  </p>
<p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact Schering Corporation, a subsidiary of Merck &amp; Co., Inc., at 1-800-526-4099 or FDA at 1-800-FDA-1088 or </span><span class="Italics">www.fda.gov/medwatch</span><span class="Bold">.</span> </p>
</div>
<div></div>
<div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
</div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div><ul><li>
<span class="Italics">Fluvoxamine (strong CYP1A2 inhibitor) and Paroxetine (CYP2D6 substrate and inhibitor):</span> cautiously approach coadministration with SAPHRIS. (<a href="#S7.1">7.1</a>, <a href="#S7.2">7.2</a>)</li></ul></div>
<div></div>
<div><div></div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>USE IN SPECIFIC POPULATIONS</span></h1>
<div><ul>
<li>
<span class="Italics">Pregnancy:</span> Use SAPHRIS during pregnancy only if the potential benefit justifies the potential risk. (<a href="#S8.1">8.1</a>)</li>
<li>
<span class="Italics">Nursing Mothers:</span> Breast feeding is not recommended. (<a href="#S8.3">8.3</a>)</li>
<li>
<span class="Italics">Pediatric Use:</span> Safety and effectiveness have not been established. (<a href="#S8.4">8.4</a>)</li>
<li>
<span class="Italics"><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span>:</span> No dose adjustment needed. (<a href="#S8.6">8.6</a>)</li>
<li>
<span class="Italics"><span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span>:</span> SAPHRIS is not recommended in patients with severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> (Child-Pugh C). (<a href="#S2.4">2.4</a>, <a href="#S8.7">8.7</a>, <a href="#S12.3">12.3</a>)</li>
</ul></div>
<div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
</div>
<div></div>
<div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
</div>
<div><div>
<div></div>
<div></div>
<div></div>
</div></div>
<div>
<div></div>
<div>
<div></div>
<div></div>
</div>
</div>
<div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION.</p>
<p class="HighlightsRevision">Revised: 1/2011</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc"><span class="Emphasis">WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">DEMENTIA</span>-RELATED <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">PSYCHOSIS</span></span></a></h1>
<h1><a href="#section-1" class="toc">1 INDICATIONS AND USAGE</a></h1>
<h2><a href="#section-1.1" class="toc">1.1	<span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">Schizophrenia</span></a></h2>
<h2><a href="#section-1.2" class="toc">1.2	Bipolar Disorder</a></h2>
<h1><a href="#section-2" class="toc">2 DOSAGE AND ADMINISTRATION</a></h1>
<h2><a href="#section-2.1" class="toc">2.1	Administration Instructions</a></h2>
<h2><a href="#section-2.2" class="toc">2.2	<span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">Schizophrenia</span></a></h2>
<h2><a href="#section-2.3" class="toc">2.3	Bipolar Disorder</a></h2>
<h2><a href="#section-2.4" class="toc">2.4	Dosage in Special Populations</a></h2>
<h2><a href="#section-2.5" class="toc">2.5	Switching from Other Antipsychotics</a></h2>
<h1><a href="#section-3" class="toc">3 DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4 CONTRAINDICATIONS</a></h1>
<h1><a href="#section-5" class="toc">5 WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1	Increased Mortality in Elderly Patients with <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">Dementia</span>-Related <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">Psychosis</span></a></h2>
<h2><a href="#section-5.2" class="toc">5.2	Cerebrovascular Adverse Events, Including <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">Stroke</span>, In Elderly Patients with <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">Dementia</span>-Related <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">Psychosis</span></a></h2>
<h2><a href="#section-5.3" class="toc">5.3	<span class="product-label-link" type="condition" conceptid="379802" conceptname="Neuroleptic malignant syndrome">Neuroleptic Malignant Syndrome</span></a></h2>
<h2><a href="#section-5.4" class="toc">5.4	<span class="product-label-link" type="condition" conceptid="4010823" conceptname="Tardive dyskinesia">Tardive Dyskinesia</span></a></h2>
<h2><a href="#section-5.5" class="toc">5.5	<span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">Hyperglycemia</span> and <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">Diabetes</span> Mellitus</a></h2>
<h2><a href="#section-5.6" class="toc">5.6	<span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">Weight Gain</span></a></h2>
<h2><a href="#section-5.7" class="toc">5.7	<span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">Orthostatic Hypotension</span>, <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">Syncope</span>, and Other Hemodynamic Effects</a></h2>
<h2><a href="#section-5.8" class="toc">5.8	<span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">Leukopenia</span>, <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">Neutropenia</span>, and <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">Agranulocytosis</span></a></h2>
<h2><a href="#section-5.9" class="toc">5.9	QT Prolongation</a></h2>
<h2><a href="#section-5.10" class="toc">5.10	<span class="product-label-link" type="condition" conceptid="4030186" conceptname="Hyperprolactinemia">Hyperprolactinemia</span></a></h2>
<h2><a href="#section-5.11" class="toc">5.11	<span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizures</span></a></h2>
<h2><a href="#section-5.12" class="toc">5.12	Potential for Cognitive and Motor Impairment</a></h2>
<h2><a href="#section-5.13" class="toc">5.13	Body Temperature Regulation</a></h2>
<h2><a href="#section-5.14" class="toc">5.14	<span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">Suicide</span></a></h2>
<h2><a href="#section-5.15" class="toc">5.15	<span class="product-label-link" type="condition" conceptid="31317" conceptname="Dysphagia">Dysphagia</span></a></h2>
<h2><a href="#section-5.16" class="toc">5.16	Use in Patients with Concomitant Illness</a></h2>
<h1><a href="#section-6" class="toc">6 ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">6.1	Overall Adverse Reactions Profile</a></h2>
<h2><a href="#section-6.2" class="toc">6.2	Clinical Studies Experience</a></h2>
<h2><a href="#section-6.3" class="toc">6.3	Postmarketing Experience</a></h2>
<h1><a href="#section-7" class="toc">7 DRUG INTERACTIONS</a></h1>
<h2><a href="#section-7.1" class="toc">7.1	Potential for Other Drugs to Affect SAPHRIS</a></h2>
<h2><a href="#section-7.2" class="toc">7.2	Potential for SAPHRIS to Affect Other Drugs</a></h2>
<h1><a href="#section-8" class="toc">8 USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-8.1" class="toc">8.1 Pregnancy</a></h2>
<h2><a href="#section-8.2" class="toc">8.2 Labor and Delivery</a></h2>
<h2><a href="#section-8.3" class="toc">8.3 Nursing Mothers</a></h2>
<h2><a href="#section-8.4" class="toc">8.4 Pediatric Use</a></h2>
<h2><a href="#section-8.5" class="toc">8.5 Geriatric Use</a></h2>
<h2><a href="#section-8.6" class="toc">8.6	<span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></a></h2>
<h2><a href="#section-8.7" class="toc">8.7	<span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></a></h2>
<h1><a href="#section-9" class="toc">9 DRUG ABUSE AND <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">DEPENDENCE</span></a></h1>
<h2><a href="#section-9.1" class="toc">9.1 Controlled Substance</a></h2>
<h2><a href="#section-9.2" class="toc">9.2 Abuse</a></h2>
<h1><a href="#section-10" class="toc">10 OVERDOSAGE</a></h1>
<h2><a href="#section-10.1" class="toc"></a></h2>
<h2><a href="#section-10.2" class="toc"></a></h2>
<h1><a href="#section-11" class="toc">11 DESCRIPTION</a></h1>
<h1><a href="#section-12" class="toc">12 CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-12.1" class="toc">12.1 Mechanism of Action</a></h2>
<h2><a href="#section-12.2" class="toc">12.2 Pharmacodynamics</a></h2>
<h2><a href="#section-12.3" class="toc">12.3 Pharmacokinetics</a></h2>
<h2><a href="#section-12.4" class="toc"></a></h2>
<h1><a href="#section-13" class="toc">13 NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-13.1" class="toc">13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2>
<h1><a href="#section-14" class="toc">14 CLINICAL STUDIES</a></h1>
<h2><a href="#section-14.1" class="toc">14.1	<span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">Schizophrenia</span></a></h2>
<h2><a href="#section-14.2" class="toc">14.2	Bipolar Disorder</a></h2>
<h1><a href="#section-15" class="toc">16 HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h2><a href="#section-15.1" class="toc"></a></h2>
<h2><a href="#section-15.2" class="toc"></a></h2>
<h1><a href="#section-16" class="toc">17 PATIENT COUNSELING INFORMATION</a></h1>
<h2><a href="#section-16.1" class="toc">17.1	Tablet Administration</a></h2>
<h2><a href="#section-16.2" class="toc">17.2	Increased Mortality in Elderly Patients with <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">Dementia</span>-Related <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">Psychosis</span></a></h2>
<h2><a href="#section-16.3" class="toc">17.3	<span class="product-label-link" type="condition" conceptid="379802" conceptname="Neuroleptic malignant syndrome">Neuroleptic Malignant Syndrome</span></a></h2>
<h2><a href="#section-16.4" class="toc">17.4	<span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">Hyperglycemia</span> and <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">Diabetes</span> Mellitus </a></h2>
<h2><a href="#section-16.5" class="toc">17.5	<span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">Weight Gain</span></a></h2>
<h2><a href="#section-16.6" class="toc">17.6	<span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">Orthostatic Hypotension</span></a></h2>
<h2><a href="#section-16.7" class="toc">17.7	<span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">Leukopenia</span>/<span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">Neutropenia</span> </a></h2>
<h2><a href="#section-16.8" class="toc">17.8	Interference with Cognitive and Motor Performance</a></h2>
<h2><a href="#section-16.9" class="toc">17.9	Heat Exposure and <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">Dehydration</span></a></h2>
<h2><a href="#section-16.10" class="toc">17.10	Concomitant Medication and Alcohol</a></h2>
<h2><a href="#section-16.11" class="toc">17.11	Pregnancy and Nursing</a></h2>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="DLDE"></a><a name="section-1"></a><p></p>
</div>
<div class="Warning">
<a name="BOX"></a><a name="section-1"></a><p></p>
<h1><span class="Emphasis">WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">DEMENTIA</span>-RELATED <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">PSYCHOSIS</span></span></h1>
<p class="First"><span class="Bold">            Elderly patients with <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span>-related <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span> treated with antipsychotic drugs are at an increased risk of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. Analyses of 17 placebo-controlled trials (modal duration of 10 weeks), largely in patients taking atypical antipsychotic drugs, revealed a risk of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> in the drug-treated patients of between 1.6 to 1.7 times that seen in placebo-treated patients. Over the course of a typical 10-week controlled trial, the rate of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> in drug-treated patients was about 4.5%, compared to a rate of about 2.6% in the placebo group. Although the causes of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> were varied, most of the <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span> appeared to be either cardiovascular (e.g., <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>, <span class="product-label-link" type="condition" conceptid="4132309" conceptname="Sudden death">sudden death</span>) or infectious (e.g., <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span>) in nature. Observational studies suggest that, similar to atypical antipsychotic drugs, treatment with conventional antipsychotic drugs may increase mortality. The extent to which the findings of increased mortality in observational studies may be attributed to the antipsychotic drug as opposed to some characteristic(s) of the patients is not clear. SAPHRIS<span class="Sup">®</span> (asenapine) is not approved for the treatment of patients with <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span>-related <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span> <span class="Italics">[see <a href="#S5.1">Warnings and Precautions (5.1)</a>]</span>.</span></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="S1"></a><a name="section-1"></a><p></p>
<h1>1 INDICATIONS AND USAGE</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="S1.1"></a><a name="section-1.1"></a><p></p>
<h2>1.1	<span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">Schizophrenia</span></h2>
<p class="First" style="border-left:1px solid;"><span class="XmChange">SAPHRIS is indicated for the treatment of <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span>. The efficacy of SAPHRIS was established in two 6-week trials and one maintenance trial in adults <span class="Italics">[</span><span class="Italics">see <a href="#S14.1">Clinical Studies (14.1)</a>]</span>.</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S1.2"></a><a name="section-1.2"></a><p></p>
<h2>1.2	Bipolar Disorder</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-1.2.1"></a><p></p>
<h3></h3>
<p class="First" style="border-left:1px solid;"><span class="XmChange"><span class="Bold Italics">Monotherapy: </span>SAPHRIS is indicated for the acute treatment of <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">manic</span> or mixed episodes associated with <span class="product-label-link" type="condition" conceptid="432876" conceptname="Bipolar I disorder">bipolar I disorder</span>. Efficacy was established in two 3-week monotherapy trials in adults <span class="Italics">[see <a href="#S14.2">Clinical Studies (14.2)</a>]</span>.</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-1.2.2"></a><p></p>
<h3></h3>
<p class="First" style="border-left:1px solid;"><span class="XmChange"><span class="Bold Italics">Adjunctive Therapy:</span> SAPHRIS is indicated as adjunctive therapy with either lithium or valproate for the acute treatment of <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">manic</span> or mixed episodes associated with <span class="product-label-link" type="condition" conceptid="432876" conceptname="Bipolar I disorder">bipolar I disorder</span>. Efficacy was established in one 3-week adjunctive trial in adults <span class="Italics">[see <a href="#S14.2">Clinical Studies (14.2)</a>].</span></span></p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="S2"></a><a name="section-2"></a><p></p>
<h1>2 DOSAGE AND ADMINISTRATION</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="S2.1"></a><a name="section-2.1"></a><p></p>
<h2>2.1	Administration Instructions</h2>
<p class="First">SAPHRIS is a sublingual tablet. To ensure optimal absorption, patients should be instructed to place the tablet under the tongue and allow it to dissolve completely. The tablet will dissolve in saliva within seconds. SAPHRIS sublingual tablets should not be crushed, chewed, or swallowed <span class="Italics">[see  <a href="#S12.3">Clinical Pharmacology (12.3)</a>]</span>. Patients should be instructed to not eat or drink for 10 minutes after administration <span class="Italics">[see <a href="#S12.3">Clinical Pharmacology (12.3)</a> and <a href="#S17.1">Patient Counseling Information (17.1)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S2.2"></a><a name="section-2.2"></a><p></p>
<h2>2.2	<span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">Schizophrenia</span></h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2.2.1"></a><p></p>
<h3></h3>
<p class="First" style="border-left:1px solid;"><span class="XmChange"><span class="Bold Italics">Usual Dose for Acute Treatment in Adults:</span> The recommended starting and target dose of SAPHRIS is 5 mg given twice daily. In short term controlled trials, there was no suggestion of added benefit with a 10 mg twice daily dose, but there was a clear increase in certain adverse reactions. The safety of doses above 10 mg twice daily has not been evaluated in clinical studies.</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2.2.2"></a><p></p>
<h3></h3>
<p class="First" style="border-left:1px solid;"><span class="XmChange"><span class="Bold Italics">Maintenance Treatment:</span> Efficacy was demonstrated with SAPHRIS in a maintenance trial in patients with <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span>. The starting dose in this study was 5 mg twice daily with an increase up to 10 mg twice daily after 1 week based on tolerability <span class="Italics">[see <a href="#S14.1">Clinical Studies (14.1</a>)]</span>. While there is no body of evidence available to answer the question of how long the schizophrenic patient should remain on SAPHRIS, patients should be periodically reassessed to determine the need for maintenance treatment.</span></p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S2.3"></a><a name="section-2.3"></a><p></p>
<h2>2.3	Bipolar Disorder</h2>
<p class="First" style="border-left:1px solid;"><span class="XmChange"><span class="Bold Italics">Usual Dose for Acute Treatment of <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">Manic</span> or Mixed Episodes Associated with <span class="product-label-link" type="condition" conceptid="432876" conceptname="Bipolar I disorder">Bipolar I Disorder</span> in Adults: </span></span></p>
<p style="border-left:1px solid;"><span class="XmChange"><span class="Italics"><span class="Underline">Monotherapy:</span></span> The recommended starting dose of SAPHRIS, and the dose maintained by 90% of the patients studied, is 10 mg twice daily. The dose can be decreased to 5 mg twice daily if warranted by adverse effects or based on individual tolerability.</span></p>
<p style="border-left:1px solid;"><span class="XmChange">In controlled monotherapy trials, the starting dose for SAPHRIS was 10 mg twice daily. On the second and subsequent days of the trials, the dose could be lowered to 5 mg twice daily, based on tolerability, but less than 10% of patients had their dose reduced. The safety of doses above 10 mg twice daily has not been evaluated in clinical trials.</span></p>
<p style="border-left:1px solid;"><span class="XmChange"><span class="Italics"><span class="Underline">Adjunctive Therapy:</span></span> The recommended starting dose of SAPHRIS is 5 mg twice daily when administered as adjunctive therapy with either lithium or valproate. Depending on the clinical response and tolerability in the individual patient, the dose can be increased to 10 mg twice daily. The safety of doses above 10 mg twice daily as adjunctive therapy with lithium or valproate has not been evaluated in clinical trials.</span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2.3.1"></a><p></p>
<h3></h3>
<p class="First" style="border-left:1px solid;"><span class="XmChange"><span class="Bold Italics">Maintenance Treatment:</span> While there is no body of evidence available to answer the question of how long the bipolar patient should remain on SAPHRIS, whether used as monotherapy or as adjunctive therapy with lithium or valproate, it is generally recommended that responding patients be continued beyond the acute response. If SAPHRIS is used for extended periods in bipolar disorder, the physician should periodically re-evaluate the long-term risks and benefits of the drug for the individual patient.</span></p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S2.4"></a><a name="section-2.4"></a><p></p>
<h2>2.4	Dosage in Special Populations</h2>
<p class="First">In a study of subjects with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> who were treated with a single dose of SAPHRIS 5 mg, there were increases in asenapine exposures (compared to subjects with normal hepatic function), that correlated with the degree of <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>. While the results indicated that no dosage adjustments are required in patients with mild (Child-Pugh A) or moderate (Child-Pugh B) <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>, there was a 7-fold increase (on average) in asenapine concentrations in subjects with severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> (Child-Pugh C) compared to the concentrations of those in subjects with normal hepatic function. Therefore, SAPHRIS is not recommended in patients with severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> <span class="Italics">[see <a href="#S8.7">Use in Special Populations (8.7)</a>]</span>. Dosage adjustments are not routinely required on the basis of age, gender, race, or <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> status <span class="Italics">[</span><span class="Italics">see Use in <a href="#S8.4">Specific Populations (8.4</a><a href="#S8.5">, 8.5</a><a href="#S8.6">, 8.6</a>) and <a href="#S12.3">Clinical Pharmacology (12.3)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S2.5"></a><a name="section-2.5"></a><p></p>
<h2>2.5	Switching from Other Antipsychotics</h2>
<p class="First">There are no systematically collected data to specifically address switching patients with <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span> or bipolar <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">mania</span> from other antipsychotics to SAPHRIS or concerning concomitant administration with other antipsychotics. While immediate discontinuation of the previous antipsychotic treatment may be acceptable for some patients with <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span>, more gradual discontinuation may be most appropriate for others. In all cases, the period of overlapping antipsychotic administration should be minimized.</p>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="S3"></a><a name="section-3"></a><p></p>
<h1>3 DOSAGE FORMS AND STRENGTHS</h1>
<ul class="Disc">
<li>SAPHRIS   5-mg tablets are round, white- to off-white sublingual tablets, with "5"   on one side.</li>
<li>SAPHRIS   10-mg tablets are round, white- to off-white sublingual tablets, with "10"   on one side.</li>
<li>SAPHRIS   5-mg tablets, black cherry flavor, are round, white- to off-white   sublingual tablets, with "5" on one side within a circle.</li>
<li>SAPHRIS   10-mg tablets, black cherry flavor, are round, white- to off-white sublingual   tablets, with "10" on one side within a circle.</li>
</ul>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="S4"></a><a name="section-4"></a><p></p>
<h1>4 CONTRAINDICATIONS</h1>
<p class="First">None</p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="S5"></a><a name="section-5"></a><p></p>
<h1>5 WARNINGS AND PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.1"></a><a name="section-5.1"></a><p></p>
<h2>5.1	Increased Mortality in Elderly Patients with <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">Dementia</span>-Related <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">Psychosis</span></h2>
<p class="First"><span class="Bold">Elderly patients with <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span>-related <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span> treated with antipsychotic drugs are at an increased risk of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. SAPHRIS is not approved for the treatment of patients with <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span>-related <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span> <span class="Italics">[see <a href="#Box">Boxed Warning</a>]</span>.</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.2"></a><a name="section-5.2"></a><p></p>
<h2>5.2	Cerebrovascular Adverse Events, Including <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">Stroke</span>, In Elderly Patients with <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">Dementia</span>-Related <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">Psychosis</span></h2>
<p class="First">In placebo-controlled trials with risperidone, aripiprazole, and olanzapine in elderly subjects with <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span>, there was a higher incidence of cerebrovascular adverse reactions (<span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">cerebrovascular accidents</span> and <span class="product-label-link" type="condition" conceptid="373503" conceptname="Transient cerebral ischemia">transient ischemic attacks</span>) including fatalities compared to placebo-treated subjects. SAPHRIS is not approved for the treatment of patients with <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span>-related <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span> <span class="Italics">[see also <a href="#Box">Boxed Warning</a> and <a href="#S5.1">Warnings and Precautions (5.1)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.3"></a><a name="section-5.3"></a><p></p>
<h2>5.3	<span class="product-label-link" type="condition" conceptid="379802" conceptname="Neuroleptic malignant syndrome">Neuroleptic Malignant Syndrome</span></h2>
<p class="First">A potentially fatal symptom complex sometimes referred to as <span class="product-label-link" type="condition" conceptid="379802" conceptname="Neuroleptic malignant syndrome">Neuroleptic Malignant Syndrome</span> (NMS) has been reported in association with administration of antipsychotic drugs, including SAPHRIS. Clinical manifestations of NMS are <span class="product-label-link" type="condition" conceptid="4260205" conceptname="Hyperpyrexia">hyperpyrexia</span>, <span class="product-label-link" type="condition" conceptid="4050941" conceptname="Muscle rigidity">muscle rigidity</span>, altered mental status, and evidence of <span class="product-label-link" type="condition" conceptid="434633" conceptname="Disorder of autonomic nervous system">autonomic instability</span> (<span class="product-label-link" type="condition" conceptid="4088122" conceptname="Heart irregular">irregular pulse</span> or blood pressure, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">diaphoresis</span>, and cardiac dysrhythmia). Additional signs may include elevated creatine phosphokinase, <span class="product-label-link" type="condition" conceptid="439142" conceptname="Myoglobinuria">myoglobinuria</span> (<span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span>), and <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">acute renal failure</span>.</p>
<p>The diagnostic evaluation of patients with this syndrome is complicated. It is important to exclude cases where the clinical presentation includes both serious medical illness (e.g. <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span>, systemic <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>) and untreated or inadequately treated extrapyramidal signs and symptoms (EPS). Other important considerations in the differential diagnosis include central anticholinergic toxicity, <span class="product-label-link" type="condition" conceptid="4181404" conceptname="Heat stroke">heat stroke</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">drug fever</span>, and primary central nervous system pathology.</p>
<p>The management of NMS should include: 1) immediate discontinuation of antipsychotic drugs and other drugs not essential to concurrent therapy; 2) intensive symptomatic treatment and medical monitoring; and 3) treatment of any concomitant serious medical problems for which specific treatments are available. There is no general agreement about specific pharmacological treatment regimens for NMS.</p>
<p>If a patient requires antipsychotic drug treatment after recovery from NMS, the potential reintroduction of drug therapy should be carefully considered. The patient should be carefully monitored, since recurrences of NMS have been reported.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.4"></a><a name="section-5.4"></a><p></p>
<h2>5.4	<span class="product-label-link" type="condition" conceptid="4010823" conceptname="Tardive dyskinesia">Tardive Dyskinesia</span></h2>
<p class="First">A syndrome of potentially irreversible, involuntary, dyskinetic movements can develop in patients treated with antipsychotic drugs. Although the prevalence of the syndrome appears to be highest among the elderly, especially elderly women, it is impossible to rely upon prevalence estimates to predict, at the inception of antipsychotic treatment, which patients are likely to develop the syndrome. Whether antipsychotic drug products differ in their potential to cause <span class="product-label-link" type="condition" conceptid="4010823" conceptname="Tardive dyskinesia">Tardive Dyskinesia</span> (TD) is unknown.</p>
<p>The risk of developing TD and the likelihood that it will become irreversible are believed to increase as the duration of treatment and the total cumulative dose of antipsychotic drugs administered to the patient increase. However, the syndrome can develop, although much less commonly, after relatively brief treatment periods at low doses.</p>
<p>There is no known treatment for established cases of TD, although the syndrome may remit, partially or completely, if antipsychotic treatment is withdrawn. Antipsychotic treatment, itself, however, may suppress (or partially suppress) the signs and symptoms of the syndrome and thereby may possibly mask the underlying process. The effect that symptomatic suppression has upon the long-term course of the syndrome is unknown.</p>
<p>Given these considerations, SAPHRIS should be prescribed in a manner that is most likely to minimize the occurrence of TD. Chronic antipsychotic treatment should generally be reserved for patients who suffer from a chronic illness that (1) is known to respond to antipsychotic drugs, and (2) for whom alternative, equally effective, but potentially less harmful treatments are not available or appropriate. In patients who do require chronic treatment, the smallest dose and the shortest duration of treatment producing a satisfactory clinical response should be sought. The need for continued treatment should be reassessed periodically.</p>
<p>If signs and symptoms of TD appear in a patient on SAPHRIS, drug discontinuation should be considered. However, some patients may require treatment with SAPHRIS despite the presence of the syndrome.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.5"></a><a name="section-5.5"></a><p></p>
<h2>5.5	<span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">Hyperglycemia</span> and <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">Diabetes</span> Mellitus</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">Hyperglycemia</span>, in some cases extreme and associated with <span class="product-label-link" type="condition" conceptid="4209145" conceptname="Ketoacidosis">ketoacidosis</span> or hyperosmolar <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span> or <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>, has been reported in patients treated with atypical antipsychotics. Assessment of the relationship between atypical antipsychotic use and glucose abnormalities is complicated by the possibility of an increased background risk of <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus in patients with <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span> and the increasing incidence of <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus in the general population. Given these confounders, the relationship between atypical antipsychotic use and <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span>-related adverse reactions is not completely understood. However, epidemiological studies suggest an increased risk of treatment-emergent <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span>-related adverse events in patients treated with the atypical antipsychotics included in these studies. Because SAPHRIS was not marketed at the time these studies were performed, it is not known if SAPHRIS is associated with this increased risk. Precise risk estimates for <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span>-related adverse events in patients treated with atypical antipsychotics are not available.</p>
<p>Patients with an established diagnosis of <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus who are started on atypical antipsychotics should be monitored regularly for worsening of glucose control. Patients with risk factors for <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus (e.g., <span class="product-label-link" type="condition" conceptid="433736" conceptname="Obesity">obesity</span>, family history of <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>) who are starting treatment with atypical antipsychotics should undergo fasting blood glucose testing at the beginning of treatment and periodically during treatment. Any patient treated with atypical antipsychotics should be monitored for symptoms of <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span> including <span class="product-label-link" type="condition" conceptid="432454" conceptname="Excessive thirst">polydipsia</span>, <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">polyuria</span>, <span class="product-label-link" type="condition" conceptid="438872" conceptname="Excessive eating - polyphagia">polyphagia</span>, and <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>. Patients who develop symptoms of <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span> during treatment with atypical antipsychotics should undergo fasting blood glucose testing. In some cases, <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span> has resolved when the atypical antipsychotic was discontinued; however, some patients required continuation of anti-diabetic treatment despite discontinuation of the antipsychotic drug.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.6"></a><a name="section-5.6"></a><p></p>
<h2>5.6	<span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">Weight Gain</span></h2>
<p class="First">Increases in weight have been observed in pre-marketing clinical trials with SAPHRIS. Patients receiving SAPHRIS should receive regular monitoring of weight <span class="Italics">[see <a href="#S17.5">Patient Counseling Information (17.5)</a>]</span>.</p>
<p>In short-term <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span> and bipolar <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">mania</span> trials, there were differences in mean <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span> between SAPHRIS-treated and placebo-treated patients. In short-term, placebo-controlled <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span> trials, the mean <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span> was 1.1 kg for SAPHRIS-treated patients compared to 0.1 kg for placebo-treated patients. The proportion of patients with a ≥7% increase in body weight (at Endpoint) was 4.9% for SAPHRIS-treated patients versus 2% for placebo-treated patients. In short-term, placebo-controlled bipolar <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">mania</span> trials, the mean <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span> for SAPHRIS-treated patients was 1.3 kg compared to 0.2 kg for placebo-treated patients. The proportion of patients with a ≥7% increase in body weight (at Endpoint) was 5.8% for SAPHRIS-treated patients versus 0.5% for placebo-treated patients.</p>
<p>In a 52-week, double-blind, comparator-controlled trial of patients with <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span> or <span class="product-label-link" type="condition" conceptid="4286201" conceptname="Schizoaffective disorder">schizoaffective disorder</span>, the mean <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span> from baseline was 0.9 kg. The proportion of patients with a ≥7% increase in body weight (at Endpoint) was 14.7%. Table 1 provides the mean weight change from baseline and the proportion of patients with a <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span> of ≥7% categorized by Body <span class="product-label-link" type="condition" conceptid="4041088" conceptname="Mass">Mass</span> Index (BMI) at baseline:</p>
<a name="i235405ca-b978-4897-8293-a57d0e657a31"></a><table width="75%">
<caption><span>TABLE 1: Weight Change Results Categorized by BMI at Baseline: Comparator-Controlled 52-Week Study in <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">Schizophrenia</span></span></caption>
<col align="left" valign="middle" width="25%">
<col align="center" valign="middle" width="25%">
<col align="center" valign="middle" width="25%">
<col align="center" valign="middle" width="25%">
<thead><tr class="First Last">
<th class="Lrule Rrule" align="left"></th>
<th class="Rrule" align="center">BMI &lt;23<br>SAPHRIS<br>(N=295)</th>
<th class="Rrule" align="center">BMI 23 – ≤27<br>SAPHRIS<br>(N=290)</th>
<th class="Rrule" align="center">BMI &gt;27<br>SAPHRIS<br>(N=302)</th>
</tr></thead>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="left"><span class="Bold">Mean change from Baseline (kg)</span></td>
<td class="Rrule" align="center">1.7</td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">0</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left"><span class="Bold">% with ≥7% increase in body weight</span></td>
<td class="Rrule" align="center">22%</td>
<td class="Rrule" align="center">13%</td>
<td class="Rrule" align="center">9%</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.7"></a><a name="section-5.7"></a><p></p>
<h2>5.7	<span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">Orthostatic Hypotension</span>, <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">Syncope</span>, and Other Hemodynamic Effects</h2>
<p class="First">SAPHRIS may induce <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">orthostatic hypotension</span> and <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span> in some patients, especially early in treatment, because of its α1-adrenergic antagonist activity. In short-term <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span> trials, <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span> was reported in 0.2% (1/572) of patients treated with therapeutic doses (5 mg or 10 mg twice daily) of SAPHRIS, compared to 0.3% (1/378) of patients treated with placebo. In short-term bipolar <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">mania</span> trials, <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span> was reported in 0.3% (1/379) of patients treated with therapeutic doses (5 mg or 10 mg twice daily) of SAPHRIS, compared to 0% (0/203) of patients treated with placebo. During pre-marketing clinical trials with SAPHRIS, including long-term trials without comparison to placebo, <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span> was reported in 0.6% (11/1953) of patients treated with SAPHRIS.</p>
<p>Four normal volunteers in clinical pharmacology studies treated with either intravenous, oral, or sublingual SAPHRIS experienced <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>, and sinus pauses. These spontaneously resolved in 3 cases, but the fourth subject received external cardiac massage. The risk of this sequence of <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>, and sinus pause might be greater in nonpsychiatric patients compared to psychiatric patients who are possibly more adapted to certain effects of psychotropic drugs.</p>
<p>Patients should be instructed about nonpharmacologic interventions that help to reduce the occurrence of <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">orthostatic hypotension</span> (e.g., sitting on the edge of the bed for several minutes before attempting to stand in the morning and slowly rising from a seated position). SAPHRIS should be used with caution in (1) patients with known cardiovascular disease (history of <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> or <span class="product-label-link" type="condition" conceptid="4124683" conceptname="Silent myocardial ischemia">ischemic heart disease</span>, <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> or conduction abnormalities), cerebrovascular disease, or conditions which would predispose patients to <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> (<span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span>, <span class="product-label-link" type="condition" conceptid="436375" conceptname="Hypovolemia">hypovolemia</span>, and treatment with antihypertensive medications); and (2) in the elderly. SAPHRIS should be used cautiously when treating patients who receive treatment with other drugs that can induce <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>, respiratory or central nervous system <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> <span class="Italics">[see <a href="#S7">Drug Interactions (7)</a>]</span>. Monitoring of orthostatic vital signs should be considered in all such patients, and a dose reduction should be considered if <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> occurs.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.8"></a><a name="section-5.8"></a><p></p>
<h2>5.8	<span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">Leukopenia</span>, <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">Neutropenia</span>, and <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">Agranulocytosis</span></h2>
<p class="First">In clinical trial and postmarketing experience, events of <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>/<span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> have been reported temporally related to antipsychotic agents, including SAPHRIS. <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">Agranulocytosis</span> (including fatal cases) has been reported with other agents in the class.</p>
<p>Possible risk factors for <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>/<span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> include pre-existing low white blood cell count (WBC) and history of drug induced <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>/<span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>. Patients with a pre-existing low WBC or a history of drug induced <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>/<span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> should have their complete blood count (CBC) monitored frequently during the first few months of therapy and SAPHRIS should be discontinued at the first sign of decline in WBC in the absence of other causative factors.</p>
<p>Patients with <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> should be carefully monitored for <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> or other symptoms or signs of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> and treated promptly if such symptoms or signs occur. Patients with severe <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> (absolute neutrophil count &lt;1000/mm<span class="Sup">3</span>) should discontinue SAPHRIS and have their WBC followed until recovery.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.9"></a><a name="section-5.9"></a><p></p>
<h2>5.9	QT Prolongation</h2>
<p class="First">The effects of SAPHRIS on the QT/QTc interval were evaluated in a dedicated QT study. This trial involved SAPHRIS doses of 5 mg, 10 mg, 15 mg, and 20 mg twice daily, and placebo, and was conducted in 151 clinically stable patients with <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span>, with electrocardiographic assessments throughout the dosing interval at baseline and steady state. At these doses, SAPHRIS was associated with increases in QTc interval ranging from 2 to 5 msec compared to placebo. No patients treated with SAPHRIS experienced QTc increases ≥60 msec from baseline measurements, nor did any patient experience a QTc of ≥500 msec.</p>
<p>Electrocardiogram (ECG) measurements were taken at various time points during the SAPHRIS clinical trial program (5 mg or 10 mg twice daily doses). Post-baseline QT prolongations exceeding 500 msec were reported at comparable rates for SAPHRIS and placebo in these short-term trials. There were no reports of <span class="product-label-link" type="condition" conceptid="4135823" conceptname="Torsades de pointes">Torsade de Pointes</span> or any other adverse reactions associated with delayed ventricular repolarization.</p>
<p>The use of SAPHRIS should be avoided in combination with other drugs known to prolong QTc including Class 1A antiarrhythmics (e.g., quinidine, procainamide) or Class 3 antiarrhythmics (e.g., amiodarone, sotalol), antipsychotic medications (e.g., ziprasidone, chlorpromazine, thioridazine), and antibiotics (e.g., gatifloxacin, moxifloxacin). SAPHRIS should also be avoided in patients with a history of <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">cardiac arrhythmias</span> and in other circumstances that may increase the risk of the occurrence of <span class="product-label-link" type="condition" conceptid="4135823" conceptname="Torsades de pointes">torsade de pointes</span> and/or <span class="product-label-link" type="condition" conceptid="4132309" conceptname="Sudden death">sudden death</span> in association with the use of drugs that prolong the QTc interval, including <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>; <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span> or <span class="product-label-link" type="condition" conceptid="4098604" conceptname="Hypomagnesemia">hypomagnesemia</span>; and presence of congenital prolongation of the QT interval.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.10"></a><a name="section-5.10"></a><p></p>
<h2>5.10	<span class="product-label-link" type="condition" conceptid="4030186" conceptname="Hyperprolactinemia">Hyperprolactinemia</span></h2>
<p class="First">Like other drugs that antagonize dopamine D<span class="Sub">2</span> receptors, SAPHRIS can elevate prolactin levels, and the elevation can persist during chronic administration. <span class="product-label-link" type="condition" conceptid="4030186" conceptname="Hyperprolactinemia">Hyperprolactinemia</span> may suppress hypothalamic GnRH, resulting in reduced pituitary gonadotropin secretion. This, in turn, may inhibit reproductive function by impairing gonadal steroidogenesis in both female and male patients. <span class="product-label-link" type="condition" conceptid="79884" conceptname="Galactorrhea not associated with childbirth">Galactorrhea</span>, <span class="product-label-link" type="condition" conceptid="443800" conceptname="Amenorrhea">amenorrhea</span>, <span class="product-label-link" type="condition" conceptid="4168447" conceptname="Gynecomastia">gynecomastia</span>, and <span class="product-label-link" type="condition" conceptid="4216771" conceptname="Impotence">impotence</span> have been reported in patients receiving prolactin-elevating compounds. Long-standing <span class="product-label-link" type="condition" conceptid="4030186" conceptname="Hyperprolactinemia">hyperprolactinemia</span> when associated with <span class="product-label-link" type="condition" conceptid="4167354" conceptname="Hypogonadism">hypogonadism</span> may lead to decreased bone density in both female and male subjects. In SAPHRIS clinical trials, the incidences of adverse events related to abnormal prolactin levels were 0.4% versus 0% for placebo <span class="Italics">[see <a href="#S6.2">Adverse Reactions (6.2)</a>]</span>.</p>
<p>Tissue culture experiments indicate that approximately one-third of human breast cancers are prolactin-dependent <span class="Italics">in vitro</span>, a factor of potential importance if the prescription of these drugs is considered in a patient with previously-detected breast cancer. Neither clinical studies nor epidemiologic studies conducted to date have shown an association between chronic administration of this class of drugs and tumorigenesis in humans, but the available evidence is too limited to be conclusive.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.11"></a><a name="section-5.11"></a><p></p>
<h2>5.11	<span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizures</span></h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizures</span> were reported in 0% and 0.3% (0/572, 1/379) of patients treated with doses of 5 mg and 10 mg twice daily of SAPHRIS, respectively, compared to 0% (0/503, 0/203) of patients treated with placebo in short-term <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span> and bipolar <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">mania</span> trials, respectively. During pre-marketing clinical trials with SAPHRIS, including long-term trials without comparison to placebo, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> were reported in 0.3% (5/1953) of patients treated with SAPHRIS. As with other antipsychotic drugs, SAPHRIS should be used with caution in patients with a history of <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> or with conditions that potentially lower the <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> threshold, e.g., Alzheimer's <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span>. Conditions that lower the <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> threshold may be more prevalent in patients 65 years or older.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.12"></a><a name="section-5.12"></a><p></p>
<h2>5.12	Potential for Cognitive and Motor Impairment</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Somnolence</span> was reported in patients treated with SAPHRIS. It was usually transient with the highest incidence reported during the first week of treatment. In short-term, fixed-dose, placebo-controlled <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span> trials, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span> was reported in 15% (41/274) of patients on SAPHRIS 5 mg twice daily and in 13% (26/208) of patients on SAPHRIS 10 mg twice daily compared to 7% (26/378) of placebo patients. In short-term, placebo-controlled bipolar <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">mania</span> trials of therapeutic doses (5–10 mg twice daily), <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span> was reported in 24% (90/379) of patients on SAPHRIS compared to 6% (13/203) of placebo patients. During pre-marketing clinical trials with SAPHRIS, including long-term trials without comparison to placebo, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span> was reported in 18% (358/1953) of patients treated with SAPHRIS. <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Somnolence</span> (including sedation) led to discontinuation in 0.6% (12/1953) of patients in short-term, placebo-controlled trials.</p>
<p>Patients should be cautioned about performing activities requiring mental alertness, such as operating hazardous machinery or operating a motor vehicle, until they are reasonably certain that SAPHRIS therapy does not affect them adversely.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.13"></a><a name="section-5.13"></a><p></p>
<h2>5.13	Body Temperature Regulation</h2>
<p class="First">Disruption of the body's ability to reduce core body temperature has been attributed to antipsychotic agents. In the short-term placebo-controlled trials for both <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span> and acute bipolar disorder, the incidence of adverse reactions suggestive of body temperature increases was low (≤1%) and comparable to placebo. During pre-marketing clinical trials with SAPHRIS, including long-term trials without comparison to placebo, the incidence of adverse reactions suggestive of body temperature increases (<span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">pyrexia</span> and <span class="product-label-link" type="condition" conceptid="4141161" conceptname="Hot">feeling hot</span>) was ≤1%. Appropriate care is advised when prescribing SAPHRIS for patients who will be experiencing conditions that may contribute to an elevation in core body temperature, e.g., exercising strenuously, exposure to extreme heat, receiving concomitant medication with anticholinergic activity, or being subject to <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.14"></a><a name="section-5.14"></a><p></p>
<h2>5.14	<span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">Suicide</span></h2>
<p class="First">The possibility of a <span class="product-label-link" type="condition" conceptid="4219484" conceptname="Suicide attempt">suicide attempt</span> is inherent in <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychotic</span> illnesses and bipolar disorder, and close supervision of high-risk patients should accompany drug therapy. Prescriptions for SAPHRIS should be written for the smallest quantity of tablets consistent with good patient management in order to reduce the risk of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.15"></a><a name="section-5.15"></a><p></p>
<h2>5.15	<span class="product-label-link" type="condition" conceptid="31317" conceptname="Dysphagia">Dysphagia</span></h2>
<p class="First">Esophageal dysmotility and <span class="product-label-link" type="condition" conceptid="4239038" conceptname="Pulmonary aspiration">aspiration</span> have been associated with antipsychotic drug use. <span class="product-label-link" type="condition" conceptid="31317" conceptname="Dysphagia">Dysphagia</span> was reported in 0.2% and 0% (1/572, 0/379) of patients treated with therapeutic doses (5–10 mg twice daily) of SAPHRIS as compared to 0% (0/378, 0/203) of patients treated with placebo in short-term <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span> and bipolar <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">mania</span> trials, respectively. During pre-marketing clinical trials with SAPHRIS, including long-term trials without comparison to placebo, <span class="product-label-link" type="condition" conceptid="31317" conceptname="Dysphagia">dysphagia</span> was reported in 0.1% (2/1953) of patients treated with SAPHRIS.</p>
<p><span class="product-label-link" type="condition" conceptid="252663" conceptname="Pneumonitis due to inhalation of food or vomitus">Aspiration pneumonia</span> is a common cause of morbidity and mortality in elderly patients, in particular those with advanced Alzheimer's <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span>. SAPHRIS is not indicated for the treatment of <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span>-related <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span>, and should not be used in patients at risk for <span class="product-label-link" type="condition" conceptid="252663" conceptname="Pneumonitis due to inhalation of food or vomitus">aspiration pneumonia</span> <span class="Italics">[see also <a href="#S5.1">Warnings and Precautions (5.1)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.16"></a><a name="section-5.16"></a><p></p>
<h2>5.16	Use in Patients with Concomitant Illness</h2>
<p class="First">Clinical experience with SAPHRIS in patients with certain concomitant systemic illnesses is limited <span class="Italics">[see <a href="#S12.3">Clinical Pharmacology (12.3)</a>]</span>.</p>
<p>SAPHRIS has not been evaluated in patients with a recent history of <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> or unstable heart disease. Patients with these diagnoses were excluded from pre-marketing clinical trials. Because of the risk of <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">orthostatic hypotension</span> with SAPHRIS, caution should be observed in cardiac patients <span class="Italics">[see <a href="#S5.6">Warnings and Precautions (5.6)</a>]</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="S6"></a><a name="section-6"></a><p></p>
<h1>6 ADVERSE REACTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="S6.1"></a><a name="section-6.1"></a><p></p>
<h2>6.1	Overall Adverse Reactions Profile</h2>
<p class="First">The following adverse reactions are discussed in more detail in other sections of the labeling:</p>
<ul>
<li>Use in Elderly Patients with <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">Dementia</span>-Related <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">Psychosis</span> <span class="Italics">[see <a href="#BOX">Boxed Warning</a> and <a href="#S5.1">Warnings and Precautions (5.1</a><a href="#S5.2"> and 5.2)</a>]</span>
</li>
<li><span class="product-label-link" type="condition" conceptid="379802" conceptname="Neuroleptic malignant syndrome">Neuroleptic Malignant Syndrome</span> <span class="Italics">[see <a href="#S5.3">Warnings and Precautions (5.3)</a>]</span>
</li>
<li><span class="product-label-link" type="condition" conceptid="4010823" conceptname="Tardive dyskinesia">Tardive Dyskinesia</span> <span class="Italics">[see <a href="#S5.4">Warnings and Precautions (5.4)</a>]</span>
</li>
<li><span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">Hyperglycemia</span> and <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">Diabetes</span> Mellitus <span class="Italics">[see <a href="#S5.5">Warnings and Precautions (5.5)</a>]</span>
</li>
<li><span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">Weight Gain</span> <span class="Italics">[see <a href="#S5.6">Warnings and Precautions (5.6)</a>]</span>
</li>
<li><span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">Orthostatic Hypotension</span>, <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">Syncope</span>, and other Hemodynamic Effects <span class="Italics">[see <a href="#S5.7">Warnings and Precautions (5.7)</a>]</span>
</li>
<li><span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">Leukopenia</span>, <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">Neutropenia</span>, and <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">Agranulocytosis</span> <span class="Italics">[see <a href="#S5.8">Warnings and Precautions (5.8)</a>]</span>
</li>
<li>QT Interval Prolongation <span class="Italics">[see <a href="#S5.9">Warnings and Precautions (5.9)</a>]</span>
</li>
<li><span class="product-label-link" type="condition" conceptid="4030186" conceptname="Hyperprolactinemia">Hyperprolactinemia</span> <span class="Italics">[see <a href="#S5.10">Warnings and Precautions (5.10)</a>]</span>
</li>
<li><span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizures</span> <span class="Italics">[see <a href="#S5.11">Warnings and Precautions (5.11)</a>]</span>
</li>
<li>Potential for Cognitive and Motor Impairment <span class="Italics">[see <a href="#S5.12">Warnings and Precautions (5.12)</a>]</span>
</li>
<li>Body Temperature Regulation <span class="Italics">[see <a href="#S5.13">Warnings and Precautions (5.13)</a>]</span>
</li>
<li><span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">Suicide</span> <span class="Italics">[see <a href="#S5.14">Warnings and Precautions (5.14)</a>]</span>
</li>
<li><span class="product-label-link" type="condition" conceptid="31317" conceptname="Dysphagia">Dysphagia</span> <span class="Italics">[see <a href="#S5.15">Warnings and Precautions (5.15)</a>]</span>
</li>
<li>Use in Patients with Concomitant Illness <span class="Italics">[see <a href="#S5.16">Warnings and Precautions (5.16)</a>]</span>
</li>
</ul>
<p>The most common adverse reactions (≥5% and at least twice the rate of placebo) reported with acute treatment in <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span> were <span class="product-label-link" type="condition" conceptid="4108925" conceptname="Akathisia">akathisia</span>, oral <span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">hypoesthesia</span>, and <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>. The safety profile of SAPHRIS in the maintenance treatment of <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span> was similar to that seen with acute treatment.</p>
<p>The most common adverse reactions (≥5% and at least twice the rate of placebo) reported with acute monotherapy treatment of <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">manic</span> or mixed episodes associated with <span class="product-label-link" type="condition" conceptid="432876" conceptname="Bipolar I disorder">bipolar I disorder</span> were <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="373747" conceptname="Extrapyramidal disease">extrapyramidal symptoms</span> other than <span class="product-label-link" type="condition" conceptid="4108925" conceptname="Akathisia">akathisia</span>, and <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight increased</span> and during the adjunctive therapy trial in bipolar disorder were <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span> and oral <span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">hypoesthesia</span>.</p>
<p>The information below is derived from a clinical trial database for SAPHRIS consisting of over 4565 patients and/or normal subjects exposed to one or more sublingual doses of SAPHRIS. A total of 1314 SAPHRIS-treated patients were treated for at least 24 weeks and 785 SAPHRIS-treated patients had at least 52 weeks of exposure at therapeutic doses.</p>
<p>The stated frequencies of adverse reactions represent the proportion of individuals who experienced a treatment-emergent adverse event of the type listed. A reaction was considered treatment emergent if it occurred for the first time or worsened while receiving therapy following baseline evaluation.</p>
<p>The figures in the tables and tabulations cannot be used to predict the incidence of side effects in the course of usual medical practice where patient characteristics and other factors differ from those that prevailed in the clinical trials. Similarly, the cited frequencies cannot be compared with figures obtained from other clinical investigations involving different treatment, uses, and investigators. The cited figures, however, do provide the prescriber with some basis for estimating the relative contribution of drug and nondrug factors to the adverse reaction incidence in the population studied.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S6.2"></a><a name="section-6.2"></a><p></p>
<h2>6.2	Clinical Studies Experience</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.2.1"></a><p></p>
<h3></h3>
<p class="First"><span class="Bold Italics">Adult Patients with <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">Schizophrenia</span>: </span>The following findings are based on the short-term placebo-controlled pre-marketing trials for <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span> (a pool of three 6-week fixed-dose trials and one 6-week flexible-dose trial) in which sublingual SAPHRIS was administered in doses ranging from 5 to 10 mg twice daily.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.2.1.1"></a><p></p>
<h4></h4>
<p class="First"><span class="Italics"><span class="Underline">Adverse Reactions Associated with Discontinuation of Treatment:</span></span> A total of 9% of SAPHRIS-treated subjects and 10% of placebo subjects discontinued due to adverse reactions. There were no drug-related adverse reactions associated with discontinuation in subjects treated with SAPHRIS at the rate of at least 1% and at least twice the placebo rate.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.2.1.2"></a><p></p>
<h4></h4>
<p class="First"><span class="Italics"><span class="Underline">Adverse Reactions Occurring at an Incidence of 2% or More in SAPHRIS-Treated Schizophrenic Patients:</span></span> Adverse reactions associated with the use of SAPHRIS (incidence of 2% or greater, rounded to the nearest percent, and SAPHRIS incidence greater than placebo) that occurred during acute therapy (up to 6-weeks in patients with <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span>) are shown in Table 2.</p>
<a name="i9311f880-094b-40b8-8ef2-c5bd32de6955"></a><table width="100%">
<caption><span>TABLE 2: Adverse Reactions Reported in 2% or More of Subjects in One of the SAPHRIS Dose Groups and Which Occurred at Greater Incidence Than in the Placebo Group in 6-Week <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">Schizophrenia</span> Trials</span></caption>
<col align="left" valign="middle" width="40%">
<col align="center" valign="middle" width="15%">
<col align="center" valign="middle" width="15%">
<col align="center" valign="middle" width="15%">
<col align="center" valign="middle" width="15%">
<thead>
<tr class="First">
<th class="Lrule Rrule" align="center">System Organ Class / Preferred Term</th>
<th class="Rrule" align="center">Placebo</th>
<th class="Rrule" align="center">SAPHRIS 5 mg twice daily</th>
<th class="Rrule" align="center">SAPHRIS 10 mg twice daily</th>
<th class="Rrule" align="center">All SAPHRIS<a name="footnote-reference-1" href="#footnote-1" class="Sup">*</a><br>5 mg or 10 mg twice daily</th>
</tr>
<tr class="Last">
<th class="Lrule Rrule" align="left"></th>
<th class="Rrule" align="center">(N=378)</th>
<th class="Rrule" align="center">(N=274)</th>
<th class="Rrule" align="center">(N=208)</th>
<th class="Rrule" align="center">(N=572)</th>
</tr>
</thead>
<tfoot><tr><td colspan="5" align="left"><dl class="Footnote">
<dt><a name="footnote-1" href="#footnote-reference-1">*</a></dt>
<dd>Also includes the Flexible-dose trial (N=90).</dd>
<dt><a name="footnote-2" href="#footnote-reference-2">†</a></dt>
<dd><span class="product-label-link" type="condition" conceptid="4108925" conceptname="Akathisia">Akathisia</span> includes: <span class="product-label-link" type="condition" conceptid="4108925" conceptname="Akathisia">akathisia</span> and <span class="product-label-link" type="condition" conceptid="4195305" conceptname="Hyperactive behavior">hyperkinesia</span>.</dd>
<dt><a name="footnote-3" href="#footnote-reference-3">‡</a></dt>
<dd><span class="product-label-link" type="condition" conceptid="373747" conceptname="Extrapyramidal disease">Extrapyramidal symptoms</span> included <span class="product-label-link" type="condition" conceptid="375800" conceptname="Dystonia">dystonia</span>, <span class="product-label-link" type="condition" conceptid="4205592" conceptname="Oculogyric crisis">oculogyration</span>, <span class="product-label-link" type="condition" conceptid="4047115" conceptname="Oral dyskinesia">dyskinesia</span>, <span class="product-label-link" type="condition" conceptid="4010823" conceptname="Tardive dyskinesia">tardive dyskinesia</span>, <span class="product-label-link" type="condition" conceptid="4050941" conceptname="Muscle rigidity">muscle rigidity</span>, <span class="product-label-link" type="condition" conceptid="4140090" conceptname="Parkinsonism">parkinsonism</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>, and <span class="product-label-link" type="condition" conceptid="373747" conceptname="Extrapyramidal disease">extrapyramidal disorder</span> (excluding <span class="product-label-link" type="condition" conceptid="4108925" conceptname="Akathisia">akathisia</span>).</dd>
<dt><a name="footnote-4" href="#footnote-reference-4">§</a></dt>
<dd><span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Somnolence</span> includes the following events: <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, sedation, and <span class="product-label-link" type="condition" conceptid="438134" conceptname="Hypersomnia">hypersomnia</span>.</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="left"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal disorders</span></span></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span></td>
<td class="Rrule" align="center">6%</td>
<td class="Rrule" align="center">7%</td>
<td class="Rrule" align="center">4%</td>
<td class="Rrule" align="center">5%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">Dry mouth</span></td>
<td class="Rrule" align="center">1%</td>
<td class="Rrule" align="center">3%</td>
<td class="Rrule" align="center">1%</td>
<td class="Rrule" align="center">2%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  Oral <span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">hypoesthesia</span></td>
<td class="Rrule" align="center">1%</td>
<td class="Rrule" align="center">6%</td>
<td class="Rrule" align="center">7%</td>
<td class="Rrule" align="center">5%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="4207204" conceptname="Excessive salivation">Salivary hypersecretion</span></td>
<td class="Rrule" align="center">0%</td>
<td class="Rrule" align="center">&lt;1%</td>
<td class="Rrule" align="center">4%</td>
<td class="Rrule" align="center">2%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="4152197" conceptname="Stomach ache">Stomach discomfort</span></td>
<td class="Rrule" align="center">1%</td>
<td class="Rrule" align="center">&lt;1%</td>
<td class="Rrule" align="center">3%</td>
<td class="Rrule" align="center">2%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></td>
<td class="Rrule" align="center">5%</td>
<td class="Rrule" align="center">4%</td>
<td class="Rrule" align="center">7%</td>
<td class="Rrule" align="center">5%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="Bold">General disorders</span></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">Fatigue</span></td>
<td class="Rrule" align="center">3%</td>
<td class="Rrule" align="center">4%</td>
<td class="Rrule" align="center">3%</td>
<td class="Rrule" align="center">3%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">Irritability</span></td>
<td class="Rrule" align="center">&lt;1%</td>
<td class="Rrule" align="center">2%</td>
<td class="Rrule" align="center">1%</td>
<td class="Rrule" align="center">2%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="Bold">Investigations</span></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">Weight increased</span></td>
<td class="Rrule" align="center">&lt;1%</td>
<td class="Rrule" align="center">2%</td>
<td class="Rrule" align="center">2%</td>
<td class="Rrule" align="center">3%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="Bold">Metabolism disorders</span></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="4217027" conceptname="Increased appetite">Increased appetite</span></td>
<td class="Rrule" align="center">&lt;1%</td>
<td class="Rrule" align="center">3%</td>
<td class="Rrule" align="center">0%</td>
<td class="Rrule" align="center">2%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="Bold"><span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">Nervous system disorders</span></span></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="4108925" conceptname="Akathisia">Akathisia</span><a name="footnote-reference-2" href="#footnote-2" class="Sup">†</a>
</td>
<td class="Rrule" align="center">3%</td>
<td class="Rrule" align="center">4%</td>
<td class="Rrule" align="center">11%</td>
<td class="Rrule" align="center">6%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span></td>
<td class="Rrule" align="center">4%</td>
<td class="Rrule" align="center">7%</td>
<td class="Rrule" align="center">3%</td>
<td class="Rrule" align="center">5%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="373747" conceptname="Extrapyramidal disease">Extrapyramidal symptoms</span><br>     (excluding <span class="product-label-link" type="condition" conceptid="4108925" conceptname="Akathisia">akathisia</span>)<a name="footnote-reference-3" href="#footnote-3" class="Sup">‡</a>
</td>
<td class="Rrule" align="center" valign="top">7%</td>
<td class="Rrule" align="center" valign="top">9%</td>
<td class="Rrule" align="center" valign="top">12%</td>
<td class="Rrule" align="center" valign="top">10%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Somnolence</span><a name="footnote-reference-4" href="#footnote-4" class="Sup">§</a>
</td>
<td class="Rrule" align="center">7%</td>
<td class="Rrule" align="center">15%</td>
<td class="Rrule" align="center">13%</td>
<td class="Rrule" align="center">13%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="Bold">Psychiatric disorders</span></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">Insomnia</span></td>
<td class="Rrule" align="center">13%</td>
<td class="Rrule" align="center">16%</td>
<td class="Rrule" align="center">15%</td>
<td class="Rrule" align="center">15%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="Bold"><span class="product-label-link" type="condition" conceptid="443784" conceptname="Vascular disorder">Vascular disorders</span></span></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span></td>
<td class="Rrule" align="center">2%</td>
<td class="Rrule" align="center">2%</td>
<td class="Rrule" align="center">3%</td>
<td class="Rrule" align="center">2%</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.2.1.3"></a><p></p>
<h4></h4>
<p class="First"><span class="Italics"><span class="Underline">Dose-Related Adverse Reactions:</span></span> Of all the adverse reactions listed in Table 2, the only apparent dose-related adverse reaction was <span class="product-label-link" type="condition" conceptid="4108925" conceptname="Akathisia">akathisia</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.2.2"></a><p></p>
<h3></h3>
<p class="First"><span class="Bold Italics">Monotherapy in Adult Patients with Bipolar <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">Mania</span>:</span> The following findings are based on the short-term placebo-controlled trials for bipolar <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">mania</span> (a pool of two 3-week flexible-dose trials) in which sublingual SAPHRIS was administered in doses of 5 mg or 10 mg twice daily.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.2.2.1"></a><p></p>
<h4></h4>
<p class="First"><span class="Italics"><span class="Underline">Adverse Reactions Associated with Discontinuation of Treatment: </span></span>Approximately 10% (38/379) of SAPHRIS-treated patients in short-term, placebo-controlled trials discontinued treatment due to an adverse reaction, compared with about 6% (12/203) on placebo. The most common adverse reactions associated with discontinuation in subjects treated with SAPHRIS (rates at least 1% and at least twice the placebo rate) were <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span> (1.1%) and oral <span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">hypoesthesia</span> (1.1%) compared to placebo (0%).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.2.2.2"></a><p></p>
<h4></h4>
<p class="First"><span class="Italics"><span class="Underline">Adverse Reactions Occurring at an Incidence of 2% or More Among SAPHRIS-Treated (Monotherapy) Bipolar Patients:</span></span> Adverse reactions associated with the use of SAPHRIS (incidence of 2% or greater, rounded to the nearest percent, and SAPHRIS incidence greater than placebo) that occurred during acute monotherapy (up to 3-weeks in patients with bipolar <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">mania</span>) are shown in Table 3.</p>
<a name="i8f6f8a6f-5442-4b58-8650-4e596f510f8c"></a><table width="100%">
<caption><span>TABLE 3: Adverse Reactions Reported in 2% or More of Subjects in One of the SAPHRIS Dose Groups and Which Occurred at Greater Incidence Than in the Placebo Group in 3-Week Bipolar <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">Mania</span> Trials</span></caption>
<col align="left" valign="middle" width="50%">
<col align="center" valign="middle" width="25%">
<col align="center" valign="middle" width="25%">
<thead><tr class="First Last">
<th class="Lrule Rrule" align="center">System Organ Class / Preferred Term</th>
<th class="Rrule" align="center">Placebo<br>(N=203)</th>
<th class="Rrule" align="center">SAPHRIS<br>5 mg or 10 mg twice daily<a name="footnote-reference-5" href="#footnote-5" class="Sup">*</a><br>(N=379)</th>
</tr></thead>
<tfoot><tr><td colspan="3" align="left"><dl class="Footnote">
<dt><a name="footnote-5" href="#footnote-reference-5">*</a></dt>
<dd>SAPHRIS 5 mg to 10 mg twice daily with flexible dosing.</dd>
<dt><a name="footnote-6" href="#footnote-reference-6">†</a></dt>
<dd><span class="product-label-link" type="condition" conceptid="373747" conceptname="Extrapyramidal disease">Extrapyramidal symptoms</span> included: <span class="product-label-link" type="condition" conceptid="375800" conceptname="Dystonia">dystonia</span>, <span class="product-label-link" type="condition" conceptid="435802" conceptname="Blepharospasm">blepharospasm</span>, <span class="product-label-link" type="condition" conceptid="440814" conceptname="Torticollis">torticollis</span>, <span class="product-label-link" type="condition" conceptid="4047115" conceptname="Oral dyskinesia">dyskinesia</span>, <span class="product-label-link" type="condition" conceptid="4010823" conceptname="Tardive dyskinesia">tardive dyskinesia</span>, <span class="product-label-link" type="condition" conceptid="4050941" conceptname="Muscle rigidity">muscle rigidity</span>, <span class="product-label-link" type="condition" conceptid="4140090" conceptname="Parkinsonism">parkinsonism</span>, <span class="product-label-link" type="condition" conceptid="437643" conceptname="Abnormal gait">gait disturbance</span>, <span class="product-label-link" type="condition" conceptid="4013001" conceptname="Masklike facies">masked facies</span>, and <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span> (excluding <span class="product-label-link" type="condition" conceptid="4108925" conceptname="Akathisia">akathisia</span>).</dd>
<dt><a name="footnote-7" href="#footnote-reference-7">‡</a></dt>
<dd><span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Somnolence</span> includes the following events: <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, sedation, and <span class="product-label-link" type="condition" conceptid="438134" conceptname="Hypersomnia">hypersomnia</span>.</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="Botrule First"><td class="Lrule Rrule" align="left" colspan="3"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal disorders</span></span></td></tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">Dry mouth</span></td>
<td class="Rrule" align="center">1%</td>
<td class="Rrule" align="center">3%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">Dyspepsia</span></td>
<td class="Rrule" align="center">2%</td>
<td class="Rrule" align="center">4%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  Oral <span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">hypoesthesia</span></td>
<td class="Rrule" align="center">&lt;1%</td>
<td class="Rrule" align="center">4%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="4099176" conceptname="Toothache">Toothache</span></td>
<td class="Rrule" align="center">2%</td>
<td class="Rrule" align="center">3%</td>
</tr>
<tr class="Botrule"><td class="Lrule Rrule" align="left" colspan="3"><span class="Bold">General disorders</span></td></tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">Fatigue</span></td>
<td class="Rrule" align="center">2%</td>
<td class="Rrule" align="center">4%</td>
</tr>
<tr class="Botrule"><td class="Lrule Rrule" align="left" colspan="3"><span class="Bold">Investigations</span></td></tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">Weight increased</span></td>
<td class="Rrule" align="center">&lt;1%</td>
<td class="Rrule" align="center">5%</td>
</tr>
<tr class="Botrule"><td class="Lrule Rrule" align="left" colspan="3"><span class="Bold">Metabolism disorders</span></td></tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="4217027" conceptname="Increased appetite">Increased appetite</span></td>
<td class="Rrule" align="center">1%</td>
<td class="Rrule" align="center">4%</td>
</tr>
<tr class="Botrule"><td class="Lrule Rrule" align="left" colspan="3"><span class="Bold">Musculoskeletal and <span class="product-label-link" type="condition" conceptid="253549" conceptname="Disorder of connective tissue">connective tissue disorders</span></span></td></tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">Arthralgia</span></td>
<td class="Rrule" align="center">1%</td>
<td class="Rrule" align="center">3%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="138525" conceptname="Pain in limb">Pain in extremity</span></td>
<td class="Rrule" align="center">&lt;1%</td>
<td class="Rrule" align="center">2%</td>
</tr>
<tr class="Botrule"><td class="Lrule Rrule" align="left" colspan="3"><span class="Bold"><span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">Nervous system disorders</span></span></td></tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="4108925" conceptname="Akathisia">Akathisia</span></td>
<td class="Rrule" align="center">2%</td>
<td class="Rrule" align="center">4%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span></td>
<td class="Rrule" align="center">3%</td>
<td class="Rrule" align="center">11%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="436235" conceptname="Taste sense altered">Dysgeusia</span></td>
<td class="Rrule" align="center">&lt;1%</td>
<td class="Rrule" align="center">3%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></td>
<td class="Rrule" align="center">11%</td>
<td class="Rrule" align="center">12%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  Other <span class="product-label-link" type="condition" conceptid="373747" conceptname="Extrapyramidal disease">extrapyramidal symptoms</span>             (excluding <span class="product-label-link" type="condition" conceptid="4108925" conceptname="Akathisia">akathisia</span>)<a name="footnote-reference-6" href="#footnote-6" class="Sup">†</a>
</td>
<td class="Rrule" align="center" valign="top">2%</td>
<td class="Rrule" align="center" valign="top">7%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Somnolence</span><a name="footnote-reference-7" href="#footnote-7" class="Sup">‡</a>
</td>
<td class="Rrule" align="center">6%</td>
<td class="Rrule" align="center">24%</td>
</tr>
<tr class="Botrule"><td class="Lrule Rrule" align="left" colspan="3"><span class="Bold">Psychiatric disorders</span></td></tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">Anxiety</span></td>
<td class="Rrule" align="center">2%</td>
<td class="Rrule" align="center">4%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depression</span></td>
<td class="Rrule" align="center">1%</td>
<td class="Rrule" align="center">2%</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">Insomnia</span></td>
<td class="Rrule" align="center">5%</td>
<td class="Rrule" align="center">6%</td>
</tr>
</tbody>
</table>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.2.3"></a><p></p>
<h3></h3>
<p class="First"><span class="Bold Italics">Adjunctive Therapy in Adult Patients with Bipolar <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">Mania</span>:</span> The following findings are based on a 12 week placebo-controlled trial (with a 3 week efficacy endpoint) in adult patients with bipolar <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">mania</span> in which sublingual SAPHRIS was administered in doses of 5 mg or 10 mg twice daily as adjunctive therapy with lithium or valproate.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.2.3.1"></a><p></p>
<h4></h4>
<p class="First"><span class="Italics"><span class="Underline">Adverse Reactions Associated with Discontinuation of Treatment:</span></span> Approximately 16% (25/158) of SAPHRIS-treated patients discontinued treatment due to an adverse reaction, compared with about 11% (18/166) on placebo. The most common adverse reactions associated with discontinuation in subjects treated with SAPHRIS (rates at least 1% and at least twice the placebo rate) were <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> (2.5%), <span class="product-label-link" type="condition" conceptid="4092095" conceptname="Planning suicide">suicidal ideation</span> (2.5%), bipolar 1 disorder (1.9%), <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span> (1.9%) and <span class="product-label-link" type="condition" conceptid="4191716" conceptname="Symptoms of depression">depressive symptoms</span> (1.3%).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.2.3.2"></a><p></p>
<h4></h4>
<p class="First"><span class="Italics"><span class="Underline">Adverse Reactions Occurring at an Incidence of 2% or More Among SAPHRIS-Treated (Adjunctive) Bipolar Patients:</span></span> Adverse reactions associated with the use of SAPHRIS (incidence of 2% or greater, rounded to the nearest percent, and SAPHRIS incidence greater than placebo) that occurred during acute adjunctive therapy at 3 weeks, a time when most of the patients were still participating in the trial, are shown in Table 4.</p>
<a name="i5f1cf480-ae74-410d-8d68-acfb3197cc21"></a><table width="100%">
<caption><span>TABLE 4: Adverse Reactions Reported in 2% or More Among SAPHRIS-Treated (Adjunctive) Bipolar <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">Mania</span> Patients and Which Occurred at Greater Incidence Than in the Placebo Group at 3 Weeks:</span></caption>
<col align="left" valign="middle" width="50%">
<col align="center" valign="middle" width="25%">
<col align="center" valign="middle" width="25%">
<thead><tr class="First Last">
<th class="Lrule Rrule" align="center">System Organ Class / Preferred Term</th>
<th class="Rrule" align="center">Placebo<br>(N=166)</th>
<th class="Rrule" align="center">SAPHRIS<br>5 mg or 10 mg twice daily<a name="footnote-reference-8" href="#footnote-8" class="Sup">*</a><br>(N=158)</th>
</tr></thead>
<tfoot><tr><td colspan="3" align="left"><dl class="Footnote">
<dt><a name="footnote-8" href="#footnote-reference-8">*</a></dt>
<dd>SAPHRIS 5 mg to 10 mg twice daily with flexible dosing.</dd>
<dt><a name="footnote-9" href="#footnote-reference-9">†</a></dt>
<dd><span class="product-label-link" type="condition" conceptid="373747" conceptname="Extrapyramidal disease">Extrapyramidal symptoms</span> included: <span class="product-label-link" type="condition" conceptid="375800" conceptname="Dystonia">dystonia</span>, <span class="product-label-link" type="condition" conceptid="4140090" conceptname="Parkinsonism">parkinsonism</span>, <span class="product-label-link" type="condition" conceptid="4205592" conceptname="Oculogyric crisis">oculogyration</span>, and <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span> (excluding <span class="product-label-link" type="condition" conceptid="4108925" conceptname="Akathisia">akathisia</span>).</dd>
<dt><a name="footnote-10" href="#footnote-reference-10">‡</a></dt>
<dd><span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Somnolence</span> includes the following events: <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span> and sedation.</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="Botrule First"><td class="Lrule Rrule" align="left" colspan="3"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal disorders</span></span></td></tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">Dyspepsia</span></td>
<td class="Rrule" align="center">2%</td>
<td class="Rrule" align="center">3%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  Oral <span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">hypoesthesia</span></td>
<td class="Rrule" align="center">0%</td>
<td class="Rrule" align="center">5%</td>
</tr>
<tr class="Botrule"><td class="Lrule Rrule" align="left" colspan="3"><span class="Bold">General disorders</span></td></tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">Fatigue</span></td>
<td class="Rrule" align="center">2%</td>
<td class="Rrule" align="center">4%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">Edema peripheral</span></td>
<td class="Rrule" align="center">&lt;1%</td>
<td class="Rrule" align="center">3%</td>
</tr>
<tr class="Botrule"><td class="Lrule Rrule" align="left" colspan="3"><span class="Bold">Investigations</span></td></tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">Weight increased</span></td>
<td class="Rrule" align="center">0%</td>
<td class="Rrule" align="center">3%</td>
</tr>
<tr class="Botrule"><td class="Lrule Rrule" align="left" colspan="3"><span class="Bold"><span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">Nervous system disorders</span></span></td></tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span></td>
<td class="Rrule" align="center">2%</td>
<td class="Rrule" align="center">4%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  Other <span class="product-label-link" type="condition" conceptid="373747" conceptname="Extrapyramidal disease">extrapyramidal symptoms</span> (excluding <span class="product-label-link" type="condition" conceptid="4108925" conceptname="Akathisia">akathisia</span>)<a name="footnote-reference-9" href="#footnote-9" class="Sup">†</a>
</td>
<td class="Rrule" align="center" valign="top">5%</td>
<td class="Rrule" align="center" valign="top">6%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Somnolence</span><a name="footnote-reference-10" href="#footnote-10" class="Sup">‡</a>
</td>
<td class="Rrule" align="center">10%</td>
<td class="Rrule" align="center">22%</td>
</tr>
<tr class="Botrule"><td class="Lrule Rrule" align="left" colspan="3"><span class="Bold">Psychiatric disorders</span></td></tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">Insomnia</span></td>
<td class="Rrule" align="center">8%</td>
<td class="Rrule" align="center">10%</td>
</tr>
<tr class="Botrule"><td class="Lrule Rrule" align="left" colspan="3"><span class="Bold"><span class="product-label-link" type="condition" conceptid="443784" conceptname="Vascular disorder">Vascular disorders</span></span></td></tr>
<tr class="Last">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span></td>
<td class="Rrule" align="center">&lt;1%</td>
<td class="Rrule" align="center">3%</td>
</tr>
</tbody>
</table>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.2.4"></a><p></p>
<h3></h3>
<p class="First"><span class="Bold Italics"><span class="product-label-link" type="condition" conceptid="375800" conceptname="Dystonia">Dystonia</span>: </span><span class="Italics"><span class="Underline">Antipsychotic Class Effect:</span></span> Symptoms of <span class="product-label-link" type="condition" conceptid="375800" conceptname="Dystonia">dystonia</span>, prolonged abnormal contractions of muscle groups, may occur in susceptible individuals during the first few days of treatment. Dystonic symptoms include: spasm of the neck muscles, sometimes progressing to tightness of the throat, swallowing difficulty, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">difficulty breathing</span>, and/or protrusion of the tongue. While these symptoms can occur at low doses, they occur more frequently and with greater severity with high potency and at higher doses of first generation antipsychotic drugs. An elevated risk of <span class="product-label-link" type="condition" conceptid="375800" conceptname="Dystonia">acute dystonia</span> is observed in males and younger age groups.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.2.5"></a><p></p>
<h3></h3>
<p class="First"><span class="Bold Italics"><span class="product-label-link" type="condition" conceptid="373747" conceptname="Extrapyramidal disease">Extrapyramidal Symptoms</span>:</span> In the short-term, placebo-controlled <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span> and bipolar <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">mania</span> trials, data was objectively collected on the Simpson Angus Rating Scale for <span class="product-label-link" type="condition" conceptid="373747" conceptname="Extrapyramidal disease">extrapyramidal symptoms</span> (EPS), the Barnes <span class="product-label-link" type="condition" conceptid="4108925" conceptname="Akathisia">Akathisia</span> Scale (for <span class="product-label-link" type="condition" conceptid="4108925" conceptname="Akathisia">akathisia</span>) and the Assessments of Involuntary Movement Scales (for <span class="product-label-link" type="condition" conceptid="4047115" conceptname="Oral dyskinesia">dyskinesias</span>). The mean change from baseline for the all-SAPHRIS 5 mg or 10 mg twice daily treated group was comparable to placebo in each of the rating scale scores.</p>
<p>In the short-term, placebo-controlled <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span> trials, the incidence of reported EPS-related events, excluding events related to <span class="product-label-link" type="condition" conceptid="4108925" conceptname="Akathisia">akathisia</span>, for SAPHRIS-treated patients was 10% versus 7% for placebo; and the incidence of <span class="product-label-link" type="condition" conceptid="4108925" conceptname="Akathisia">akathisia</span>-related events for SAPHRIS-treated patients was 6% versus 3% for placebo. In short-term placebo-controlled bipolar <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">mania</span> trials, the incidence of EPS-related events, excluding events related to <span class="product-label-link" type="condition" conceptid="4108925" conceptname="Akathisia">akathisia</span>, for SAPHRIS-treated patients was 7% versus 2% for placebo; and the incidence of <span class="product-label-link" type="condition" conceptid="4108925" conceptname="Akathisia">akathisia</span>-related events for SAPHRIS-treated patients was 4% versus 2% for placebo.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.2.6"></a><p></p>
<h3></h3>
<p class="First"><span class="Bold Italics">Laboratory Test Abnormalities:</span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.2.6.1"></a><p></p>
<h4></h4>
<p class="First"><span class="Italics"><span class="Underline">Glucose:</span></span> The effects on fasting serum glucose levels in the short-term <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span> and bipolar <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">mania</span> trials revealed no clinically relevant mean changes <span class="Italics">[see also <a href="#S5.5">Warnings and Precautions (5.5)</a>]. </span>In the short-term placebo-controlled <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span> trials, the mean increase in fasting glucose levels for SAPHRIS-treated patients was 3.2 mg/dL compared to a decrease of 1.6 mg/dL for placebo-treated patients. The proportion of patients with fasting glucose elevations ≥126 mg/dL (at Endpoint), was 7.4% for SAPHRIS-treated patients versus 6% for placebo-treated patients. In the short-term, placebo-controlled bipolar <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">mania</span> trials, the mean decreases in fasting glucose levels for both SAPHRIS-treated and placebo-treated patients were 0.6 mg/dL. The proportion of patients with fasting glucose elevations ≥126 mg/dL (at Endpoint), was 4.9% for SAPHRIS-treated patients versus 2.2% for placebo-treated patients.</p>
<p>In a 52-week, double-blind, comparator-controlled trial of patients with <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span> and <span class="product-label-link" type="condition" conceptid="4286201" conceptname="Schizoaffective disorder">schizoaffective disorder</span>, the mean increase from baseline of fasting glucose was 2.4 mg/dL.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.2.6.2"></a><p></p>
<h4></h4>
<p class="First"><span class="Italics"><span class="Underline">Lipids:</span></span> The effects on total <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> and fasting triglycerides in the short-term <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span> and bipolar <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">mania</span> trials revealed no clinically relevant mean changes. In short-term, placebo-controlled <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span> trials, the mean increase in total <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> levels for SAPHRIS-treated patients was 0.4 mg/dL compared to a decrease of 3.6 mg/dL for placebo-treated patients. The proportion of patients with total <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> elevations ≥240 mg/dL (at Endpoint) was 8.3% for SAPHRIS-treated patients versus 7% for placebo-treated patients. In short-term, placebo-controlled bipolar <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">mania</span> trials, the mean increase in total <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> levels for SAPHRIS-treated patients was 1.1 mg/dL compared to a decrease of 1.5 mg/dL in placebo-treated patients. The proportion of patients with total <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> elevations ≥240 mg/dL (at Endpoint) was 8.7% for SAPHRIS-treated patients versus 8.6% for placebo-treated patients. In short-term, placebo-controlled <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span> trials, the mean increase in triglyceride levels for SAPHRIS-treated patients was 3.8 mg/dL compared to a decrease of 13.5 mg/dL for placebo-treated patients. The proportion of patients with elevations in triglycerides ≥200 mg/dL (at Endpoint) was 13.2% for SAPHRIS-treated patients versus 10.5% for placebo-treated patients. In short-term, placebo-controlled bipolar <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">mania</span> trials, the mean decrease in triglyceride levels for SAPHRIS-treated patients was 3.5 mg/dL versus 17.9 mg/dL for placebo-treated subjects. The proportion of patients with elevations in triglycerides ≥200 mg/dL (at Endpoint) was 15.2% for SAPHRIS-treated patients versus 11.4% for placebo-treated patients.</p>
<p>In a 52-week, double-blind, comparator-controlled trial of patients with <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span> and <span class="product-label-link" type="condition" conceptid="4286201" conceptname="Schizoaffective disorder">schizoaffective disorder</span>, the mean decrease from baseline of total <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> was 6 mg/dL and the mean decrease from baseline of fasting triglycerides was 9.8 mg/dL.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.2.6.3"></a><p></p>
<h4></h4>
<p class="First"><span class="Italics"><span class="Underline">Transaminases:</span></span> Transient elevations in serum transaminases (primarily ALT) in the short-term <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span> and bipolar <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">mania</span> trials were more common in treated patients but mean changes were not clinically relevant. In short-term, placebo-controlled <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span> trials, the mean increase in transaminase levels for SAPHRIS-treated patients was 1.6 units/L compared to a decrease of 0.4 units/L for placebo-treated patients. The proportion of patients with transaminase elevations ≥3 times ULN (at Endpoint) was 0.9% for SAPHRIS-treated patients versus 1.3% for placebo-treated patients. In short-term, placebo-controlled bipolar <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">mania</span> trials, the mean increase in transaminase levels for SAPHRIS-treated patients was 8.9 units/L compared to a decrease of 4.9 units/L in placebo-treated patients. The proportion of patients with transaminase elevations ≥3 times upper limit of normal (ULN) (at Endpoint) was 2.5% for SAPHRIS-treated patients versus 0.6% for placebo-treated patients. No cases of more severe <span class="product-label-link" type="condition" conceptid="4352876" conceptname="Liver damage">liver injury</span> were seen.</p>
<p>In a 52-week, double-blind, comparator-controlled trial of patients with <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span> and <span class="product-label-link" type="condition" conceptid="4286201" conceptname="Schizoaffective disorder">schizoaffective disorder</span>, the mean increase from baseline of ALT was 1.7 units/L.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.2.6.4"></a><p></p>
<h4></h4>
<p class="First"><span class="Italics"><span class="Underline">Prolactin:</span></span> The effects on prolactin levels in the short-term <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span> and bipolar <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">mania</span> trials revealed no clinically relevant mean changes in baseline. In short-term, placebo-controlled <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span> trials, the mean decreases in prolactin levels were 6.5 ng/mL for SAPHRIS-treated patients compared to 10.7 ng/mL for placebo-treated patients. The proportion of patients with prolactin elevations ≥4 times ULN (at Endpoint) were 2.6% for SAPHRIS-treated patients versus 0.6% for placebo-treated patients. In short-term, placebo-controlled bipolar <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">mania</span> trials, the mean increase in prolactin levels was 4.9 ng/mL for SAPHRIS-treated patients compared to a decrease of 0.2 ng/mL for placebo-treated patients. The proportion of patients with prolactin elevations ≥4 times ULN (at Endpoint) were 2.3% for SAPHRIS-treated patients versus 0.7% for placebo-treated patients.</p>
<p>In a long-term (52-week), double-blind, comparator-controlled trial of patients with <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span> and <span class="product-label-link" type="condition" conceptid="4286201" conceptname="Schizoaffective disorder">schizoaffective disorder</span>, the mean decrease in prolactin from baseline for SAPHRIS-treated patients was 26.9 ng/mL.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.2.6.5"></a><p></p>
<h4></h4>
<p class="First"><span class="Italics"><span class="Underline">Creatine Kinase (CK):</span></span> The proportion of patients with CK elevations &gt;3 times ULN at any time were 6.4% and 11.1% for patients treated with SAPHRIS 5 mg bid and 10 mg bid, respectively, as compared to 6.7% for placebo-treated patients in short-term, fixed-dose trials in <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span> and bipolar <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">mania</span>. The clinical relevance of this finding is unknown.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.2.7"></a><p></p>
<h3></h3>
<p class="First"><span class="Bold Italics">Other Adverse Reactions Observed During the Premarketing Evaluation of SAPHRIS:</span> Following is a list of MedDRA terms that reflect adverse reactions reported by patients treated with sublingual SAPHRIS at multiple doses of ≥5 mg twice daily during any phase of a trial within the database of adult patients. The reactions listed are those that could be of clinical importance, as well as reactions that are plausibly drug-related on pharmacologic or other grounds. Reactions already listed in other parts of <span class="Italics"><a href="#S6">Adverse Reactions (6)</a></span>, or those considered in <span class="Italics"><a href="#S5">Warnings and Precautions (5)</a></span> or<span class="Italics"><a href="#S10"> Overdosage (10)</a></span> are not included. Although the reactions reported occurred during treatment with SAPHRIS, they were not necessarily caused by it. Reactions are further categorized by MedDRA system organ class and listed in order of decreasing frequency according to the following definitions: those occurring in at least 1/100 patients (only those not already listed in the tabulated results from placebo-controlled trials appear in this listing); those occurring in 1/100 to 1/1000 patients; and those occurring in fewer than 1/1000 patients.</p>
<dl>
<dt> </dt>
<dd>
<span class="Italics"><span class="Underline">Blood and lymphatic disorders:</span></span><span class="Italics"> &lt;1/1000 patients: </span><span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>; <span class="Italics">≥1/1000 patients and &lt;1/100 patients:</span> <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span></dd>
<dt> </dt>
<dd>
<span class="Italics"><span class="Underline"><span class="product-label-link" type="condition" conceptid="321588" conceptname="Heart disease">Cardiac disorders</span>:</span></span><span class="Italics"> ≥1/1000 patients and &lt;1/100 patients</span><span class="Italics">:</span> <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, temporary <span class="product-label-link" type="condition" conceptid="313791" conceptname="Bundle branch block">bundle branch block</span></dd>
<dt> </dt>
<dd>
<span class="Italics"><span class="Underline"><span class="product-label-link" type="condition" conceptid="375252" conceptname="Disorder of eye">Eye disorders</span>:</span></span><span class="Italics"> ≥1/1000 patients and &lt;1/100 patients:</span> <span class="product-label-link" type="condition" conceptid="375263" conceptname="Cycloplegia">accommodation disorder</span></dd>
<dt> </dt>
<dd>
<span class="Italics"><span class="Underline"> <span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal disorders</span>:</span></span><span class="Italics"> ≥1/1000 patients and &lt;1/100 patients</span><span class="Italics">:</span> oral <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paraesthesia</span>, <span class="product-label-link" type="condition" conceptid="441334" conceptname="Glossodynia">glossodynia</span>, <span class="product-label-link" type="condition" conceptid="4222234" conceptname="Tongue swelling">swollen tongue</span></dd>
<dt> </dt>
<dd>
<span class="Italics"><span class="Underline">General disorders:</span></span><span class="Italics"> &lt;1/1000 patients:</span> idiosyncratic drug reaction</dd>
<dt> </dt>
<dd>
<span class="Italics"><span class="Underline">Investigations:</span></span><span class="Italics"> ≥1/1000 patients </span><span class="Italics">and &lt;1/100 patients</span><span class="Italics">:</span> <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">hyponatremia</span></dd>
<dt> </dt>
<dd>
<span class="Italics"><span class="Underline"><span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">Nervous system disorders</span>:</span></span><span class="Italics"> ≥1/1000 patients and &lt;1/100 patients:</span> <span class="product-label-link" type="condition" conceptid="4196636" conceptname="Dysarthria">dysarthria</span></dd>
</dl>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.3"></a><p></p>
<h2>6.3	Postmarketing Experience</h2>
<p class="First">Adverse reactions have been identified during postapproval use of SAPHRIS. Because these reactions are reported voluntarily from a population of uncertain size, it is generally not possible to reliably estimate their frequency or establish a causal relationship to drug exposure.</p>
<p>There have been postmarketing reports of serious <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span> in patients treated with SAPHRIS, including <span class="product-label-link" type="condition" conceptid="4222234" conceptname="Tongue swelling">swollen tongue</span> and swollen throat (<span class="product-label-link" type="condition" conceptid="4056883" conceptname="Edema of pharynx">pharyngeal edema</span>). The local anesthetic properties of asenapine should be considered as a possible alternative etiology for the oropharyngeal symptoms.</p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="S7"></a><a name="section-7"></a><p></p>
<h1>7 DRUG INTERACTIONS</h1>
<p class="First">The risks of using SAPHRIS in combination with other drugs have not been extensively evaluated. Given the primary CNS effects of SAPHRIS, caution should be used when it is taken in combination with other centrally-acting drugs or alcohol.</p>
<p>Because of its α1-adrenergic antagonism with potential for inducing <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, SAPHRIS may enhance the effects of certain antihypertensive agents.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="S7.1"></a><a name="section-7.1"></a><p></p>
<h2>7.1	Potential for Other Drugs to Affect SAPHRIS</h2>
<p class="First">Asenapine is cleared primarily through direct glucuronidation by UGT1A4 and oxidative metabolism by cytochrome P450 isoenzymes (predominantly CYP1A2). The potential effects of inhibitors of several of these enzyme pathways on asenapine clearance were studied.</p>
<a name="i0f8f6c87-ca11-494d-8057-937043d3c1f3"></a><table width="100%">
<caption><span>TABLE 5: Summary of Effect of Coadministered Drugs on Exposure to Asenapine in Healthy Volunteers</span></caption>
<col align="center" valign="middle" width="20%">
<col align="center" valign="middle" width="20%">
<col align="center" valign="middle" width="16%">
<col align="center" valign="middle" width="12%">
<col align="center" valign="middle" width="12%">
<col align="center" valign="middle" width="20%">
<thead>
<tr class="First">
<th class="Lrule Rrule" align="center" rowspan="2">Coadministered drug (Postulated effect on CYP450/UGT)</th>
<th class="Botrule Rrule" align="center" colspan="2">Dose schedules</th>
<th class="Botrule Rrule" align="center" colspan="2">Effect on asenapine pharmacokinetics</th>
<th class="Rrule" align="center" valign="top">Recommendation</th>
</tr>
<tr class="Botrule Last">
<th class="Rrule" align="center">Coadministered drug</th>
<th class="Rrule" align="center">Asenapine</th>
<th class="Rrule" align="center">C<span class="Sub">max</span>
</th>
<th class="Rrule" align="center">AUC<span class="Sub">0–∞</span>
</th>
<th class="Rrule" align="center"></th>
</tr>
</thead>
<tfoot><tr><td colspan="6" align="left"><dl class="Footnote">
<dt><a name="footnote-11" href="#footnote-reference-11">*</a></dt>
<dd>The full therapeutic dose of fluvoxamine would be expected to cause a greater increase in asenapine plasma concentrations. AUC: Area under the curve.</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="center">Fluvoxamine<br>(CYP1A2 inhibitor)</td>
<td class="Rrule" align="center">25 mg twice daily for 8 days</td>
<td class="Rrule" align="center">5 mg Single Dose</td>
<td class="Rrule" align="center">+13%</td>
<td class="Rrule" align="center">+29%</td>
<td class="Rrule" align="center">Coadminister with caution<a name="footnote-reference-11" href="#footnote-11" class="Sup">*</a>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center">Paroxetine<br>(CYP2D6 inhibitor)</td>
<td class="Rrule" align="center">20 mg once daily for 9 days</td>
<td class="Rrule" align="center">5 mg Single Dose</td>
<td class="Rrule" align="center">–13%</td>
<td class="Rrule" align="center">–9%</td>
<td class="Rrule" align="center">No SAPHRIS dose adjustment required <span class="Italics">[see <a href="#S7.2">Drug Interactions (7.2)</a>]</span>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center">Imipramine (CYP1A2/2C19/3A4 inhibitor)</td>
<td class="Rrule" align="center">75 mg Single Dose</td>
<td class="Rrule" align="center">5 mg Single Dose</td>
<td class="Rrule" align="center">+17%</td>
<td class="Rrule" align="center">+10%</td>
<td class="Rrule" align="center">No SAPHRIS dose adjustment required</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center">Cimetidine (CYP3A4/2D6/1A2 inhibitor)</td>
<td class="Rrule" align="center">800 mg twice daily for 8 days</td>
<td class="Rrule" align="center">5 mg Single Dose</td>
<td class="Rrule" align="center">–13%</td>
<td class="Rrule" align="center">+1%</td>
<td class="Rrule" align="center">No SAPHRIS dose adjustment required</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center">Carbamazepine<br>(CYP3A4 inducer)</td>
<td class="Rrule" align="center">400 mg twice daily for 15 days</td>
<td class="Rrule" align="center">5 mg Single Dose</td>
<td class="Rrule" align="center">–16%</td>
<td class="Rrule" align="center">–16%</td>
<td class="Rrule" align="center">No SAPHRIS dose adjustment required</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="center">Valproate<br>(UGT1A4 inhibitor)</td>
<td class="Rrule" align="center">500 mg twice daily for 9 days</td>
<td class="Rrule" align="center">5 mg Single Dose</td>
<td class="Rrule" align="center">2%</td>
<td class="Rrule" align="center">–1%</td>
<td class="Rrule" align="center">No SAPHRIS dose adjustment required</td>
</tr>
</tbody>
</table>
<p>A population pharmacokinetic analysis indicated that the concomitant administration of lithium had no effect on the pharmacokinetics of asenapine.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S7.2"></a><a name="section-7.2"></a><p></p>
<h2>7.2	Potential for SAPHRIS to Affect Other Drugs</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.2.1"></a><p></p>
<h3></h3>
<p class="First"><span class="Bold Italics">Coadministration with CYP2D6 Substrates: </span><span class="Italics">In vitro</span> studies indicate that asenapine weakly inhibits CYP2D6.</p>
<p>Following coadministration of dextromethorphan and SAPHRIS in healthy subjects, the ratio of dextrorphan/dextromethorphan (DX/DM) as a marker of CYP2D6 activity was measured. Indicative of CYP2D6 inhibition, treatment with SAPHRIS 5 mg twice daily decreased the DX/DM ratio to 0.43. In the same study, treatment with paroxetine 20 mg daily decreased the DX/DM ratio to 0.032. In a separate study, coadministration of a single 75-mg dose of imipramine with a single 5-mg dose of SAPHRIS did not affect the plasma concentrations of the metabolite desipramine (a CYP2D6 substrate). Thus, <span class="Italics">in vivo</span>, SAPHRIS appears to be at most a weak inhibitor of CYP2D6. Coadministration of a single 20-mg dose of paroxetine (a CYP2D6 substrate and inhibitor) during treatment with 5 mg SAPHRIS twice daily in 15 healthy male subjects resulted in an almost 2-fold increase in paroxetine exposure. Asenapine may enhance the inhibitory effects of paroxetine on its own metabolism.</p>
<p>SAPHRIS should be coadministered cautiously with drugs that are both substrates and inhibitors for CYP2D6.</p>
<p>Valproic acid and lithium pre-dose serum concentrations collected from an adjunctive therapy study were comparable between asenapine treated patients and placebo treated patients indicating a lack of effect of asenapine on valproic and lithium plasma levels.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="S8"></a><a name="section-8"></a><p></p>
<h1>8 USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="S8.1"></a><a name="section-8.1"></a><p></p>
<h2>8.1 Pregnancy</h2>
<div class="Section" data-sectionCode="34077-8">
<a name="section-8.1.1"></a><p></p>
<p class="First"><span class="Bold Italics">Pregnancy Category C:</span> There are no adequate and well-controlled studies of SAPHRIS in pregnant women. </p>
<p>In animal studies, asenapine increased post-implantation loss and decreased pup weight and survival at doses similar to or less than recommended clinical doses. In these studies there was no increase in the incidence of structural abnormalities caused by asenapine.</p>
<p>Asenapine was not teratogenic in reproduction studies in rats and rabbits at intravenous doses up to 1.5 mg/kg in rats and 0.44 mg/kg in rabbits. These doses are 0.7 and 0.4 times, respectively, the maximum recommended human dose (MRHD) of 10 mg twice daily given sublingually on a mg/m2 basis. Plasma levels of asenapine were measured in the rabbit study, and the area under the curve (AUC) at the highest dose tested was 2 times that in humans receiving the MRHD.</p>
<p>In a study in which rats were treated from day 6 of gestation through day 21 postpartum with intravenous doses of asenapine of 0.3, 0.9, and 1.5 mg/kg/day (0.15, 0.4, and 0.7 times the MRHD of 10 mg twice daily given sublingually on a mg/m2 basis), increases in post-implantation loss and early pup <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span> were seen at all doses, and decreases in subsequent pup survival and <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span> were seen at the two higher doses. A cross-fostering study indicated that the decreases in pup survival were largely due to prenatal drug effects. Increases in post-implantation loss and decreases in pup weight and survival were also seen when pregnant rats were dosed orally with asenapine.</p>
</div>
<div class="Section" data-sectionCode="34078-6">
<a name="section-8.1.2"></a><p></p>
<p class="First"><span class="Bold">Non-teratogenic Effects</span></p>
<p>Neonates exposed to antipsychotic drugs during the third trimester of pregnancy are at risk for extrapyramidal and/or withdrawal symptoms following delivery. There have been reports of <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span>, <span class="product-label-link" type="condition" conceptid="4208994" conceptname="Increased muscle tone">hypertonia</span>, <span class="product-label-link" type="condition" conceptid="4002033" conceptname="Muscle relaxation">hypotonia</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, <span class="product-label-link" type="condition" conceptid="4158346" conceptname="Respiratory distress">respiratory distress</span> and <span class="product-label-link" type="condition" conceptid="434750" conceptname="Feeding difficulties and mismanagement">feeding disorder</span> in these neonates. These complications have varied in severity; while in some cases symptoms have been self-limited, in other cases neonates have required intensive care unit support and prolonged hospitalization. SAPHRIS (asenapine) should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.</p>
</div>
</div>
<div class="Section" data-sectionCode="34079-4">
<a name="S8.2"></a><a name="section-8.2"></a><p></p>
<h2>8.2 Labor and Delivery</h2>
<p class="First">The effect of SAPHRIS on labor and delivery in humans is unknown.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="S8.3"></a><a name="section-8.3"></a><p></p>
<h2>8.3 Nursing Mothers</h2>
<p class="First">Asenapine is excreted in milk of rats during lactation. It is not known whether asenapine or its metabolites are excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when SAPHRIS is administered to a nursing woman. It is recommended that women receiving SAPHRIS should not breast feed.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="S8.4"></a><a name="section-8.4"></a><p></p>
<h2>8.4 Pediatric Use</h2>
<p class="First">Safety and effectiveness in pediatric patients have not been established.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="S8.5"></a><a name="section-8.5"></a><p></p>
<h2>8.5 Geriatric Use</h2>
<p class="First">Clinical studies of SAPHRIS in the treatment of <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span> and bipolar <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">mania</span> did not include sufficient numbers of patients aged 65 and over to determine whether or not they respond differently than younger patients. Of the approximately 2250 patients in pre-marketing clinical studies of SAPHRIS, 1.1% (25) were 65 years of age or over. Multiple factors that might increase the pharmacodynamic response to SAPHRIS, causing poorer tolerance or orthostasis, could be present in elderly patients, and these patients should be monitored carefully.</p>
<p>Elderly patients with <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span>-related <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span> treated with SAPHRIS are at an increased risk of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> compared to placebo. SAPHRIS is not approved for the treatment of patients with <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span>-related <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span> <span class="Italics">[see <a href="#Box">Boxed Warning</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S8.6"></a><a name="section-8.6"></a><p></p>
<h2>8.6	<span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></h2>
<p class="First">The exposure of asenapine following a single dose of 5 mg was similar among subjects with varying degrees of <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> and subjects with normal renal function <span class="Italics">[see </span><span class="Italics"><a href="#S12.3">Clinical Pharmacology (12.3)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S8.7"></a><a name="section-8.7"></a><p></p>
<h2>8.7	<span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></h2>
<p class="First">In subjects with severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> who were treated with a single dose of SAPHRIS 5 mg, asenapine exposures (on average), were 7-fold higher than the exposures observed in subjects with normal hepatic function. Thus, SAPHRIS is not recommended in patients with severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> (Child-Pugh C) <span class="Italics">[see <a href="#S2.4">Dosage and Administration (2.4)</a> and <a href="#S12.3">Clinical Pharmacology (12.3)</a>]</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="42227-9">
<a name="S9"></a><a name="section-9"></a><p></p>
<h1>9 DRUG ABUSE AND <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">DEPENDENCE</span></h1>
<div class="Section" data-sectionCode="34085-1">
<a name="S9.1"></a><a name="section-9.1"></a><p></p>
<h2>9.1 Controlled Substance</h2>
<p class="First">SAPHRIS is not a controlled substance.</p>
</div>
<div class="Section" data-sectionCode="34086-9">
<a name="S9.2"></a><a name="section-9.2"></a><p></p>
<h2>9.2 Abuse</h2>
<p class="First">SAPHRIS has not been systematically studied in animals or humans for its abuse potential or its ability to induce tolerance or physical <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span>. Thus, it is not possible to predict the extent to which a CNS-active drug will be misused, diverted and/or abused once it is marketed. Patients should be evaluated carefully for a history of drug abuse, and such patients should be observed carefully for signs that they are misusing or abusing SAPHRIS (e.g., drug-seeking behavior, increases in dose).</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="S10"></a><a name="section-10"></a><p></p>
<h1>10 OVERDOSAGE</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="section-10.1"></a><p></p>
<h2></h2>
<p class="First"><span class="Bold Italics">Human Experience:</span> In pre-marketing clinical studies involving more than 3350 patients and/or healthy subjects, accidental or intentional acute overdosage of SAPHRIS was identified in 3 patients. Among these few reported cases of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>, the highest estimated ingestion of SAPHRIS was 400 mg. Reported adverse reactions at the highest dosage included <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span> and <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-10.2"></a><p></p>
<h2></h2>
<p class="First"><span class="Bold Italics">Management of Overdosage: </span>There is no specific antidote to SAPHRIS. The possibility of multiple drug involvement should be considered. An electrocardiogram should be obtained and management of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> should concentrate on supportive therapy, maintaining an adequate airway, oxygenation and ventilation, and management of symptoms.</p>
<p><span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span> and <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">circulatory collapse</span> should be treated with appropriate measures, such as intravenous fluids and/or sympathomimetic agents (epinephrine and dopamine should not be used, since beta stimulation may worsen <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> in the setting of SAPHRIS-induced alpha blockade). In case of severe <span class="product-label-link" type="condition" conceptid="373747" conceptname="Extrapyramidal disease">extrapyramidal symptoms</span>, anticholinergic medication should be administered. Close medical supervision and monitoring should continue until the patient recovers.</p>
</div>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="S11"></a><a name="section-11"></a><p></p>
<h1>11 DESCRIPTION</h1>
<p class="First">SAPHRIS is a psychotropic agent that is available for sublingual administration. Asenapine belongs to the class dibenzo-oxepino pyrroles. The chemical designation is (3a<span class="Italics">RS</span>,12b<span class="Italics">RS</span>)-5-Chloro-2-methyl-2,3,3a,12b-tetrahydro-1<span class="Italics">H</span>dibenzo[2,3:6,7]oxepino[4,5-<span class="Italics">c</span>]pyrrole (2<span class="Italics">Z</span>)-2-butenedioate (1:1). Its molecular formula is C<span class="Sub">17</span>H<span class="Sub">16</span>ClNO•C<span class="Sub">4</span>H<span class="Sub">4</span>O<span class="Sub">4</span> and its molecular weight is 401.84 (free base: 285.8). The chemical structure is:</p>
<p><img alt="Chemical Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=03c696e9-0e6b-4e5c-be0a-41416f8019be&amp;name=saphris-01.jpg"></p>
<p>Asenapine is a white- to off-white powder.</p>
<p>SAPHRIS is supplied for sublingual administration in tablets containing 5-mg or 10-mg asenapine; inactive ingredients include gelatin and mannitol.</p>
<p>SAPHRIS, black cherry flavor, is supplied for sublingual administration in tablets containing 5-mg or 10-mg asenapine; inactive ingredients include gelatin, mannitol, sucralose, and black cherry flavor.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="S12"></a><a name="section-12"></a><p></p>
<h1>12 CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="S12.1"></a><a name="section-12.1"></a><p></p>
<h2>12.1 Mechanism of Action</h2>
<p class="First">The mechanism of action of asenapine, as with other drugs having efficacy in <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span> and bipolar disorder, is unknown. It has been suggested that the efficacy of asenapine in <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span> is mediated through a combination of antagonist activity at D<span class="Sub">2</span> and 5-HT<span class="Sub">2A</span> receptors.</p>
</div>
<div class="Section" data-sectionCode="43681-6">
<a name="S12.2"></a><a name="section-12.2"></a><p></p>
<h2>12.2 Pharmacodynamics</h2>
<p class="First">Asenapine exhibits high affinity for serotonin 5-HT<span class="Sub">1A</span>, 5-HT<span class="Sub">1B</span>, 5-HT<span class="Sub">2A</span>, 5-HT<span class="Sub">2B</span>, 5-HT<span class="Sub">2C</span>, 5-HT<span class="Sub">5</span>, 5-HT<span class="Sub">6,</span> and 5-HT<span class="Sub">7</span> receptors (Ki values of 2.5, 4.0, 0.06, 0.16, 0.03, 1.6, 0.25, and 0.13 nM), dopamine D<span class="Sub">2</span>, D<span class="Sub">3</span>, D<span class="Sub">4</span>, and D<span class="Sub">1</span> receptors (Ki values of 1.3, 0.42, 1.1, and 1.4 nM), α<span class="Sub">1</span> and α<span class="Sub">2</span>-adrenergic receptors (Ki values of 1.2 and 1.2 nM), and histamine H<span class="Sub">1</span> receptors (Ki value 1.0 nM), and moderate affinity for H<span class="Sub">2</span> receptors (Ki value of 6.2 nM). In <span class="Italics">in vitro </span>assays asenapine acts as an antagonist at these receptors. Asenapine has no appreciable affinity for muscarinic cholinergic receptors (e.g., Ki value of 8128 nM for M<span class="Sub">1</span>).</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="S12.3"></a><a name="section-12.3"></a><p></p>
<h2>12.3 Pharmacokinetics</h2>
<p class="First">Following a single 5-mg dose of SAPHRIS, the mean C<span class="Sub">max</span> was approximately 4 ng/mL and was observed at a mean t<span class="Sub">max</span> of 1 hour. Elimination of asenapine is primarily through direct glucuronidation by UGT1A4 and oxidative metabolism by cytochrome P450 isoenzymes (predominantly CYP1A2). Following an initial more rapid distribution phase, the mean terminal half-life is approximately 24 hrs. With multiple-dose twice-daily dosing, steady-state is attained within 3 days. Overall, steady-state asenapine pharmacokinetics are similar to single-dose pharmacokinetics.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-12.3.1"></a><p></p>
<h3></h3>
<p class="First"><span class="Bold Italics">Absorption: </span>Following sublingual administration, asenapine is rapidly absorbed with peak plasma concentrations occurring within 0.5 to 1.5 hours. The absolute bioavailability of sublingual asenapine at 5 mg is 35%. Increasing the dose from 5 mg to 10 mg twice daily (a two-fold increase) results in less than linear (1.7 times) increases in both the extent of exposure and maximum concentration. The absolute bioavailability of asenapine when swallowed is low (&lt;2% with an oral tablet formulation).</p>
<p>The intake of water several (2 or 5) minutes after asenapine administration resulted in decreased asenapine exposure. Therefore, eating and drinking should be avoided for 10 minutes after administration <span class="Italics">[see </span><span class="Italics"><a href="#S2.1">Dosage and Administration (2.1)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-12.3.2"></a><p></p>
<h3></h3>
<p class="First"><span class="Bold Italics">Distribution: </span>Asenapine is rapidly distributed and has a large volume of distribution (approximately 20 – 25 L/kg), indicating extensive extravascular distribution. Asenapine is highly bound (95%) to plasma proteins, including albumin and α1-acid glycoprotein.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-12.3.3"></a><p></p>
<h3></h3>
<p class="First"><span class="Bold Italics">Metabolism and Elimination: </span>Direct glucuronidation by UGT1A4 and oxidative metabolism by cytochrome P450 isoenzymes (predominantly CYP1A2) are the primary metabolic pathways for asenapine.</p>
<p>Asenapine is a high clearance drug with a clearance after intravenous administration of 52 L/h. In this circumstance, hepatic clearance is influenced primarily by changes in liver blood flow rather than by changes in the intrinsic clearance, i.e., the metabolizing enzymatic activity. Following an initial more rapid distribution phase, the terminal half life of asenapine is approximately 24 hours. Steady-state concentrations of asenapine are reached within 3 days of twice daily dosing.</p>
<p>After administration of a single dose of [<span class="Sup">14</span>C]-labeled asenapine, about 90% of the dose was recovered; approximately 50% was recovered in urine, and 40% recovered in feces. About 50% of the circulating species in plasma have been identified. The predominant species was asenapine N<span class="Sup">+</span>-glucuronide; others included N-desmethylasenapine, N-desmethylasenapine N-carbamoyl glucuronide, and unchanged asenapine in smaller amounts. SAPHRIS activity is primarily due to the parent drug.</p>
<p><span class="Italics">In vitro</span> studies indicate that asenapine is a substrate for UGT1A4, CYP1A2 and to a lesser extent CYP3A4 and CYP2D6. Asenapine is a weak inhibitor of CYP2D6. Asenapine does not cause induction of CYP1A2 or CYP3A4 activities in cultured human hepatocytes. Coadministration of asenapine with known inhibitors, inducers or substrates of these metabolic pathways has been studied in a number of drug-drug interaction studies <span class="Italics">[see <a href="#S7">Drug Interactions (7)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-12.3.4"></a><p></p>
<h3></h3>
<p class="First"><span class="Bold Italics">Smoking: </span>A population pharmacokinetic analysis indicated that smoking, which induces CYP1A2, had no effect on the clearance of asenapine in smokers. In a crossover study in which 24 healthy male subjects (who were smokers) were administered a single 5-mg sublingual dose, concomitant smoking had no effect on the pharmacokinetics of asenapine.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-12.3.5"></a><p></p>
<h3></h3>
<p class="First"><span class="Bold Italics">Food: </span>A crossover study in 26 healthy male subjects was performed to evaluate the effect of food on the pharmacokinetics of a single 5-mg dose of asenapine. Consumption of food immediately prior to sublingual administration decreased asenapine exposure by 20%; consumption of food 4 hours after sublingual administration decreased asenapine exposure by about 10%. These effects are probably due to increased hepatic blood flow.</p>
<p>In clinical trials establishing the efficacy and safety of SAPHRIS, patients were instructed to avoid eating for 10 minutes following sublingual dosing. There were no other restrictions with regard to the timing of meals in these trials <span class="Italics">[see <a href="#S2.1">Dosage and Administration (2.1)</a> and <a href="#S17.1">Patient Counseling Information (17.1)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-12.3.6"></a><p></p>
<h3></h3>
<p class="First"><span class="Bold Italics">Water: </span>In clinical trials establishing the efficacy and safety of SAPHRIS, patients were instructed to avoid drinking for 10 minutes following sublingual dosing. The effect of water administration following 10 mg sublingual SAPHRIS dosing was studied at different time points of 2, 5, 10, and 30 minutes in 15 healthy male subjects. The exposure of asenapine following administration of water 10 minutes after sublingual dosing was equivalent to that when water was administered 30 minutes after dosing. Reduced exposure to asenapine was observed following water administration at 2 minutes (19% decrease) and 5 minutes (10% decrease) <span class="Italics">[see <a href="#S2.1">Dosage and Administration (2.1)</a> and <a href="#S17.1">Patient Counseling Information (17.1)</a>]</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-12.4"></a><p></p>
<h2></h2>
<p class="First"><span class="Bold Italics">Special Populations:</span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-12.4.1"></a><p></p>
<h3></h3>
<p class="First"><span class="Italics"><span class="Underline"><span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span>:</span></span> The effect of decreased hepatic function on the pharmacokinetics of asenapine, administered as a single 5-mg sublingual dose, was studied in 30 subjects (8 each in those with normal hepatic function and Child-Pugh A and B groups, and 6 in the Child Pugh C group). In subjects with mild or moderate <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> (Child-Pugh A or B), asenapine exposure was 12% higher than that in subjects with normal hepatic function, indicating that dosage adjustment is not required for these subjects. In subjects with severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>, asenapine exposures were on average 7 times higher than the exposures of those in subjects with normal hepatic function. Thus, SAPHRIS is not recommended in patients with severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> (Child-Pugh C) <span class="Italics">[see <a href="#S2.4">Dosage in Specific Populations (2.4)</a> and <a href="#S8.7">Use in Specific Populations (8.7)</a> and <a href="#S5.14">Warnings and Precautions (5.14)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-12.4.2"></a><p></p>
<h3></h3>
<p class="First"><span class="Italics"><span class="Underline"><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span>:</span></span> The effect of decreased renal function on the pharmacokinetics of asenapine was studied in subjects with mildly (creatinine clearance (CrCl) 51 to 80 mL/min; N=8), moderately (CrCl 30 to 50 mL/min; N=8), and severely (CrCl less than 30 mL/min but not on dialysis; N=8) <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span> and compared to normal subjects (CrCl greater than 80 mL/min; N=8). The exposure of asenapine following a single dose of 5 mg was similar among subjects with varying degrees of <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> and subjects with normal renal function. Dosage adjustment based upon degree of <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> is not required. The effect of renal function on the excretion of other metabolites and the effect of dialysis on the pharmacokinetics of asenapine has not been studied <span class="Italics">[see <a href="#S8.6">Use in Specific Populations (8.6)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-12.4.3"></a><p></p>
<h3></h3>
<p class="First"><span class="Italics"><span class="Underline">Geriatric Patients</span></span><span class="Underline">:</span> In elderly patients with <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span> (65–85 years of age), asenapine concentrations were on average 30 to 40% higher compared to younger adults. When the range of exposures in the elderly was examined, the highest exposure for asenapine was up to 2-fold higher than the highest exposure in younger subjects. In a population pharmacokinetic analysis, a decrease in clearance with increasing age was observed, implying a 30% higher exposure in elderly as compared to adult patients <span class="Italics">[see <a href="#S8.5">Use in Specific Populations (8.5)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-12.4.4"></a><p></p>
<h3></h3>
<p class="First"><span class="Italics"><span class="Underline">Gender:</span></span> The potential difference in asenapine pharmacokinetics between males and females was not studied in a dedicated trial. In a population pharmacokinetic analysis, no significant differences between genders were observed.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-12.4.5"></a><p></p>
<h3></h3>
<p class="First"><span class="Italics"><span class="Underline">Race:</span></span> In a population pharmacokinetic analysis, no effect of race on asenapine concentrations was observed. In a dedicated study, the pharmacokinetics of SAPHRIS were similar in Caucasian and Japanese subjects.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="S13"></a><a name="section-13"></a><p></p>
<h1>13 NONCLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="S13.1"></a><a name="section-13.1"></a><p></p>
<h2>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-13.1.1"></a><p></p>
<h3></h3>
<p class="First"><span class="Bold Italics">Carcinogenesis:</span> In a lifetime carcinogenicity study in CD-1 mice asenapine was administered subcutaneously at doses up to those resulting in plasma levels (AUC) estimated to be 5 times those in humans receiving the MRHD of 10 mg twice daily. The incidence of <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">malignant lymphomas</span> was increased in female mice, with a no-effect dose resulting in plasma levels estimated to be 1.5 times those in humans receiving the MRHD. The mouse <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strain</span> used has a high and variable incidence of <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">malignant lymphomas</span>, and the significance of these results to humans is unknown. There were no increases in other tumor types in female mice. In male mice, there were no increases in any tumor type.</p>
<p>In a lifetime carcinogenicity study in Sprague-Dawley rats, asenapine did not cause any increases in tumors when administered subcutaneously at doses up to those resulting in plasma levels (AUC) estimated to be 5 times those in humans receiving the MRHD.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-13.1.2"></a><p></p>
<h3></h3>
<p class="First"><span class="Bold Italics">Mutagenesis:</span> No evidence for genotoxic potential of asenapine was found in the <span class="Italics">in vitro </span>bacterial reverse mutation assay, the <span class="Italics">in vitro </span>forward gene mutation assay in mouse <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> cells, the <span class="Italics">in vitro </span>chromosomal aberration assays in human <span class="product-label-link" type="condition" conceptid="4254663" conceptname="Lymphocyte count">lymphocytes</span>, the <span class="Italics">in vitro</span> sister chromatid exchange assay in rabbit <span class="product-label-link" type="condition" conceptid="4254663" conceptname="Lymphocyte count">lymphocytes</span>, or the <span class="Italics">in vivo </span>micronucleus assay in rats.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-13.1.3"></a><p></p>
<h3></h3>
<p class="First"><span class="Bold Italics">Impairment of Fertility:</span> Asenapine did not impair fertility in rats when tested at doses up to 11 mg/kg twice daily given orally. This dose is 10 times the maximum recommended human dose of 10 mg twice daily given sublingually on a mg/m<span class="Sup">2</span> basis.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="S14"></a><a name="section-14"></a><p></p>
<h1>14 CLINICAL STUDIES</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="S14.1"></a><a name="section-14.1"></a><p></p>
<h2>14.1	<span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">Schizophrenia</span></h2>
<p class="First">The efficacy of SAPHRIS in the treatment of <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span> in adults was evaluated in three fixed-dose, short-term (6 week), randomized, double-blind, placebo-controlled, and active-controlled (haloperidol, risperidone, and olanzapine) trials of adult patients who met DSM-IV criteria for <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span> and were having an acute exacerbation of their schizophrenic illness. In two of the three trials SAPHRIS demonstrated superior efficacy to placebo. In a third trial, SAPHRIS could not be distinguished from placebo; however, an active control in that trial was superior to placebo.</p>
<p>In the two positive trials for SAPHRIS<span class="Bold">, </span>the primary efficacy rating scale was the Positive and Negative Syndrome Scale (PANSS), which assesses the symptoms of <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span>. The primary endpoint was change from baseline to endpoint on the PANSS total score. The results of the SAPHRIS trials in <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span> follow:</p>
<p>In trial 1, a 6-week trial (n=174), comparing SAPHRIS (5 mg twice daily) to placebo, SAPHRIS 5 mg twice daily was statistically superior to placebo on the PANSS total score.</p>
<p>In trial 2, a 6-week trial (n=448), comparing two fixed doses of SAPHRIS (5 mg and 10 mg twice daily) to placebo, SAPHRIS 5 mg twice daily was statistically superior to placebo on the PANSS total score. SAPHRIS 10 mg twice daily showed no added benefit compared to 5 mg twice daily and was not significantly different from placebo.</p>
<p>An examination of population subgroups did not reveal any clear evidence of differential responsiveness on the basis of age, gender or race.</p>
<p>Maintenance of efficacy has been demonstrated in a placebo-controlled, double-blind, multicenter, flexible dose (5 mg or 10 mg twice daily based on tolerability) clinical trial with a randomized withdrawal design. A total of 700 patients entered open-label treatment with SAPHRIS for a period of 26 weeks. Of these, a total of 386 patients who met pre-specified criteria for continued stability (mean length of stabilization was 22 weeks) were randomized to a double-blind, placebo-controlled, randomized withdrawal phase. SAPHRIS was statistically superior to placebo in time to relapse or impending relapse defined as increase in PANSS ≥20% from baseline and a Clinical Global Impression–Severity of Illness (CGI-S) score ≥4 (at least 2 days within 1 week) or PANSS score ≥5 on "<span class="product-label-link" type="condition" conceptid="4195585" conceptname="Hostile behavior">hostility</span>" or "uncooperativeness" items and CGI-S score &gt;4 (&gt;2 days within a week), or PANSS score ≥5 on any two of the following items: "unusual thought content," "conceptual disorganization," or "hallucinatory behavior" items, and CGI-S score ≥4 (≥2 days within 1 week) or investigator judgment of worsening symptoms or increased risk of violence to self (including <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">suicide</span>) or other persons. The Kaplan-Meier curves of the time to relapse or impending relapse during the double-blind, placebo-controlled, randomized withdrawal phase of this trial for SAPHRIS and placebo are shown in Figure 1.</p>
<p><img alt="Figure 1" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=03c696e9-0e6b-4e5c-be0a-41416f8019be&amp;name=saphris-02.jpg"></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S14.2"></a><a name="section-14.2"></a><p></p>
<h2>14.2	Bipolar Disorder</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-14.2.1"></a><p></p>
<h3></h3>
<p class="First"><span class="Bold Italics">Monotherapy: </span>The efficacy of SAPHRIS in the treatment of <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">acute mania</span> was established in two similarly designed 3-week, randomized, double-blind, placebo-controlled, and active-controlled (olanzapine) trials of adult patients who met DSM-IV criteria for <span class="product-label-link" type="condition" conceptid="432876" conceptname="Bipolar I disorder">Bipolar I Disorder</span> with an acute <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">manic</span> or mixed episode with or without <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychotic</span> features.</p>
<p>The primary rating instrument used for assessing <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">manic</span> symptoms in these trials was the Young <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">Mania</span> Rating Scale (YMRS). Patients were also assessed on the Clinical Global Impression – Bipolar (CGI-BP) scale. In both trials, all patients randomized to SAPHRIS were initially administered 10 mg twice daily, and the dose could be adjusted within the dose range of 5 to 10 mg twice daily from Day 2 onward based on efficacy and tolerability. Ninety percent of patients remained on the 10 mg twice daily dose. SAPHRIS was statistically superior to placebo on the YMRS total score and the CGI-BP Severity of Illness score (<span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">mania</span>) in both studies.</p>
<p>An examination of subgroups did not reveal any clear evidence of differential responsiveness on the basis of age, gender or race.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-14.2.2"></a><p></p>
<h3></h3>
<p class="First"><span class="Bold Italics">Adjunctive Therapy: </span>The efficacy of SAPHRIS as an adjunctive therapy in <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">acute mania</span> was established in a 12-week, placebo-controlled trial with a 3-week primary efficacy endpoint involving 326 patients with a <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">manic</span> or mixed episode of <span class="product-label-link" type="condition" conceptid="432876" conceptname="Bipolar I disorder">Bipolar I Disorder</span>, with or without <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychotic</span> features, who were partially responsive to lithium or valproate monotherapy after at least 2 weeks of treatment. SAPHRIS was statistically superior to placebo in the reduction of <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">manic</span> symptoms (measured by the YMRS total score) as an adjunctive therapy to lithium or valproate monotherapy at week 3.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="S16"></a><a name="section-15"></a><p></p>
<h1>16 HOW SUPPLIED/STORAGE AND HANDLING</h1>
<p class="First">SAPHRIS (asenapine) sublingual tablets are supplied as:</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-15.1"></a><p></p>
<h2></h2>
<p class="First"><span class="Bold">5-mg Tablets </span></p>
<p>Round, white- to off-white sublingual tablets, with "5" on one side.</p>
<a name="i84681a85-7e50-47a8-84a5-fa5150300c6d"></a><table width="80%">
<col align="left" valign="middle" width="25%">
<col align="left" valign="middle" width="50%">
<col align="left" valign="middle" width="25%">
<tbody class="Headless">
<tr class="First Toprule"><td align="left" colspan="3">Child-resistant packaging</td></tr>
<tr>
<td align="left">Box of 60</td>
<td align="left">6 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blisters</span> with 10 tablets</td>
<td align="left">NDC 0052-0118-06</td>
</tr>
<tr><td align="left" colspan="3">Hospital Unit Dose</td></tr>
<tr class="Botrule Last">
<td align="left">Box of 100  </td>
<td align="left">10 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blisters</span> with 10 tablets </td>
<td align="left"> NDC 0052-0118-90</td>
</tr>
</tbody>
</table>
<p><span class="Bold">10-mg Tablets</span></p>
<p>Round, white- to off-white sublingual tablets, with "10" on one side.</p>
<a name="id291a2ba-7de5-483e-81e7-afe8312703a8"></a><table width="80%">
<col align="left" valign="middle" width="25%">
<col align="left" valign="middle" width="50%">
<col align="left" valign="middle" width="25%">
<tbody class="Headless">
<tr class="First Toprule"><td align="left" colspan="3">Child-resistant packaging</td></tr>
<tr>
<td align="left">Box of 60</td>
<td align="left">6 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blisters</span> with 10 tablets</td>
<td align="left"> NDC 0052-0119-06</td>
</tr>
<tr><td align="left" colspan="3">Hospital Unit Dose</td></tr>
<tr class="Botrule Last">
<td align="left">Box of 100</td>
<td align="left">10 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blisters</span> with 10 tablets</td>
<td align="left">NDC 0052-0119-90</td>
</tr>
</tbody>
</table>
<p><span class="Bold">5-mg Tablets, black cherry flavor</span></p>
<p>Round, white- to off-white sublingual tablets, with "5" on one side within a circle.</p>
<a name="i91563d1e-a601-4baf-8d4a-78e4b67b9061"></a><table width="80%">
<col align="left" valign="middle" width="25%">
<col align="left" valign="middle" width="50%">
<col align="left" valign="middle" width="25%">
<tbody class="Headless">
<tr class="First Toprule"><td align="left" colspan="3">Child-resistant packaging</td></tr>
<tr>
<td align="left">Box of 60</td>
<td align="left">6 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blisters</span> with 10 tablets</td>
<td align="left">NDC 0052-2139-03</td>
</tr>
<tr><td align="left" colspan="3">Hospital Unit Dose</td></tr>
<tr class="Botrule Last">
<td align="left">Box of 100</td>
<td align="left">10 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blisters</span> with 10 tablets</td>
<td align="left">NDC 0052-2139-04</td>
</tr>
</tbody>
</table>
<p><span class="Bold">10-mg Tablets, black cherry flavor</span></p>
<p>Round, white- to off-white sublingual tablets, with "10" on one side within a circle.</p>
<a name="i11f05fa2-9f42-44e2-8eb8-c1799b58925f"></a><table width="80%">
<col align="left" valign="middle" width="25%">
<col align="left" valign="middle" width="50%">
<col align="left" valign="middle" width="25%">
<tbody class="Headless">
<tr class="First Toprule"><td align="left" colspan="3">Child-resistant packaging</td></tr>
<tr>
<td align="left">Box of 60</td>
<td align="left">6 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blisters</span> with 10 tablets</td>
<td align="left">NDC 0052-2142-03</td>
</tr>
<tr><td align="left" colspan="3">Hospital Unit Dose</td></tr>
<tr class="Botrule Last">
<td align="left">Box of 100</td>
<td align="left">10 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blisters</span> with 10 tablets</td>
<td align="left">NDC 0052-2142-04</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="44425-7">
<a name="section-15.2"></a><p></p>
<h2></h2>
<p class="First"><span class="Bold">Storage</span></p>
<p><span class="Bold">   Store at 15°–30°C (59°–86°F) [<span class="Italics">see</span> USP Controlled Room Temperature].</span></p>
</div>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="S17"></a><a name="section-16"></a><p></p>
<h1>17 PATIENT COUNSELING INFORMATION</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="S17.1"></a><a name="section-16.1"></a><p></p>
<h2>17.1	Tablet Administration</h2>
<p class="First"><img alt="Figure " src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=03c696e9-0e6b-4e5c-be0a-41416f8019be&amp;name=saphris-03.jpg"></p>
<p><span class="Italics">[see <a href="#S7">Drug Interactions (7)</a> and <a href="#S12.3">Clinical Pharmacology (12.3)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S17.2"></a><a name="section-16.2"></a><p></p>
<h2>17.2	Increased Mortality in Elderly Patients with <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">Dementia</span>-Related <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">Psychosis</span></h2>
<p class="First">Patients and caregivers should be advised that elderly patients with <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span>-related psychoses treated with atypical antipsychotic drugs are at increased risk of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> compared with placebo. SAPHRIS is not approved for elderly patients with <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span>-related <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span> <span class="Italics">[see <a href="#S5.1">Warnings and Precautions (5.1)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S17.3"></a><a name="section-16.3"></a><p></p>
<h2>17.3	<span class="product-label-link" type="condition" conceptid="379802" conceptname="Neuroleptic malignant syndrome">Neuroleptic Malignant Syndrome</span></h2>
<p class="First">Patients and caregivers should be counseled that a potentially fatal symptom complex sometimes referred to as <span class="product-label-link" type="condition" conceptid="379802" conceptname="Neuroleptic malignant syndrome">Neuroleptic Malignant Syndrome</span> (NMS) has been reported in association with administration of antipsychotic drugs. Signs and symptoms of NMS include <span class="product-label-link" type="condition" conceptid="4260205" conceptname="Hyperpyrexia">hyperpyrexia</span>, <span class="product-label-link" type="condition" conceptid="4050941" conceptname="Muscle rigidity">muscle rigidity</span>, altered mental status, and evidence of <span class="product-label-link" type="condition" conceptid="434633" conceptname="Disorder of autonomic nervous system">autonomic instability</span> (<span class="product-label-link" type="condition" conceptid="4088122" conceptname="Heart irregular">irregular pulse</span> or blood pressure, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">diaphoresis</span>, and cardiac dysrhythmia) <span class="Italics">[see <a href="#S5.3">Warnings and Precautions (5.3)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S17.4"></a><a name="section-16.4"></a><p></p>
<h2>17.4	<span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">Hyperglycemia</span> and <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">Diabetes</span> Mellitus </h2>
<p class="First">Patients should be aware of the symptoms of <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span> (high blood sugar) and <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus. Patients who are diagnosed with <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>, those with risk factors for <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>, or those that develop these symptoms during treatment should have their blood glucose monitored at the beginning of and periodically during treatment <span class="Italics">[see <a href="#S5.5">Warnings and Precautions (5.5)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S17.5"></a><a name="section-16.5"></a><p></p>
<h2>17.5	<span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">Weight Gain</span></h2>
<p class="First">Patients should be advised that they may experience <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span>. Patients should have their weight monitored regularly <span class="Italics">[see <a href="#S5.6">Warnings and Precautions (5.6)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S17.6"></a><a name="section-16.6"></a><p></p>
<h2>17.6	<span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">Orthostatic Hypotension</span></h2>
<p class="First">Patients should be advised of the risk of <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">orthostatic hypotension</span> (symptoms include feeling dizzy or lightheaded upon standing) especially early in treatment, and also at times of re-initiating treatment or increases in dose <span class="Italics">[see <a href="#S5.7">Warnings and Precautions (5.7)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S17.7"></a><a name="section-16.7"></a><p></p>
<h2>17.7	<span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">Leukopenia</span>/<span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">Neutropenia</span> </h2>
<p class="First">Patients with a pre-existing low WBC or a history of drug induced <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>/<span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> should be advised that they should have their CBC monitored while taking SAPHRIS <span class="Italics">[see <a href="#S5.8">Warnings and Precautions (5.8)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S17.8"></a><a name="section-16.8"></a><p></p>
<h2>17.8	Interference with Cognitive and Motor Performance</h2>
<p class="First">Patients should be cautioned about performing activities requiring mental alertness, such as operating hazardous machinery or operating a motor vehicle, until they are reasonably certain that SAPHRIS therapy does not affect them adversely <span class="Italics">[see <a href="#S5.12">Warnings and Precautions (5.12)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S17.9"></a><a name="section-16.9"></a><p></p>
<h2>17.9	Heat Exposure and <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">Dehydration</span></h2>
<p class="First">Patients should be advised regarding appropriate care in avoiding overheating and <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span> <span class="Italics">[see <a href="#S5.13">Warnings and Precautions (5.13)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S17.10"></a><a name="section-16.10"></a><p></p>
<h2>17.10	Concomitant Medication and Alcohol</h2>
<p class="First">Patients should be advised to inform their physicians if they are taking, or plan to take, any prescription or over-the-counter medications since there is a potential for interactions. Patients should be advised to avoid alcohol while taking SAPHRIS <span class="Italics">[see <a href="#S7">Drug Interactions (7)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S17.11"></a><a name="section-16.11"></a><p></p>
<h2>17.11	Pregnancy and Nursing</h2>
<p class="First">Patients should be advised to notify their physician if they become pregnant or intend to become pregnant during therapy with SAPHRIS. Patients should be advised not to breast feed if they are taking SAPHRIS <span class="Italics">[see <a href="#S8.1">Use in Special Populations (8.1</a><a href="#S8.3">, 8.3)</a>]</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-17"></a><p></p>
<h1></h1>
<p class="First">Manufactured by: Catalent UK Swindon Zydis Ltd., Blagrove, Swindon, Wiltshire, SN5 8RU, UK</p>
<p>Distributed by: Schering Corporation, a subsidiary of <span class="Bold">MERCK &amp; CO., INC.</span>, Whitehouse Station, NJ 08889, USA</p>
<p>U.S. Patent No. 5,763,476.</p>
<p>Copyright © 2009 N.V. Organon, a subsidiary of <span class="Bold">Merck &amp; Co., Inc.</span> All rights reserved.</p>
<p>xxxxx x/xx xx</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-18"></a><p></p>
<p class="First"><span class="Bold">SAPHRIS PACKAGE LABEL - 10mg/60 tablet 
carton     </span></p>
<p><span class="Bold">Rx only</span></p>
<p><br><span class="Bold"></span></p>
<p><img alt="Label Image" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=03c696e9-0e6b-4e5c-be0a-41416f8019be&amp;name=SAPHRIS%2010MG%20LABEL%20936.jpg"></p>
<br><p><span class="Bold"><br></span></p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>SAPHRIS 		
					</strong><br><span class="contentTableReg">asenapine maleate tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:16590-936(NDC:0052-0119)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">SUBLINGUAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>ASENAPINE MALEATE</strong> (ASENAPINE) </td>
<td class="formItem">ASENAPINE MALEATE</td>
<td class="formItem">10 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>GELATIN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MANNITOL</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">white (white to off-white) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND</td>
<td class="formLabel">Size</td>
<td class="formItem">12mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">10</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:16590-936-60</td>
<td class="formItem">6  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">10  in 1 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">BLISTER</span> PACK</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA022117</td>
<td class="formItem">08/14/2009</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>STAT RX USA LLC
							(786036330)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">STAT RX USA LLC</td>
<td class="formItem"></td>
<td class="formItem">786036330</td>
<td class="formItem">relabel, repack</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 2/2011<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>9f62b6d2-6535-4eb5-9bc8-f031e15ef83b</div>
<div>Set id: 03c696e9-0e6b-4e5c-be0a-41416f8019be</div>
<div>Version: 1</div>
<div>Effective Time: 20110216</div>
</div>
</div> <div class="DistributorName">STAT RX USA LLC</div></p>
</body></html>
